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ABSTRACT:  
Myelodysplastic syndromes (MDS) are acquired heterogeneous hematopoietic 
clonal disorders primarily seen in the adult and elderly populations that presents a variety 
of cellular morphologies in cell lineages, varying prognoses, and differences in overall 
survival (OS) between individual patients.  The occurrence of MDS in the pediatric and 
young adult population, or those between the ages of 0 and 29, is slowly on the rise.  
Pediatric and elderly cases exhibit diverse cytogenetic findings with differences in OS.  
The characterization of the genetic landscape of pediatric MDS is limited and most studies 
detailing genetic changes have been conducted in adult MDS cases.  In order to aid in 
therapeutic stratification for pediatric cases, the key genes involved in hematopoietic 
transformation must be deciphered.  This study utilized comprehensive analysis including 
cytogenetic karyotyping, FISH, and high-resolution microarray techniques.  With the use 
of multiple techniques, this study confirmed the rarity of MDS in the pediatric population, 
characterized the frequencies of hallmark cytogenetic abnormalities, and identified key 
aberrations observed at the genetic level.  With the use of microarray, we were able to 
detect genomic aberrations in 33 genes including novel copy number changes in more 
than one case in the PRDM16, IRF4, MYH11, ALK, CDKN2B, PAX5, EXT2, and ERCC4 
genes.  The results from this study prove the importance of comprehensive testing utilizing 
a variety of techniques in distinguishing the most accurate genetic landscape of pediatric 
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MDS.  This information can be used to better equip the medical community in accurately 
diagnosing and providing prognostic implications for therapy and treatment. 
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Myelodysplastic syndromes (MDS) are acquired hematopoietic clonal disorders 
primarily seen in the adult and elderly populations with an overall estimate of incidence at 
14,000 new cases per year (Siegel, Ma et al. 2014).  This group of heterogeneous bone 
marrow syndromes are characterized as stem-cell disorders with varying degrees of 
overall reduction in blood cell production.  The heterogeneous nature of MDS presents as 
a variety of cellular morphologies in a number of myeloid cell lineages, varying prognoses, 
and differences in overall survival (OS) between individual patients.  The majority of 
patients present a normocellular or hyperplastic bone marrow, however, up to 20% of 
patients have shown hypoplastic and mylofibrotic bone marrow (Aul, Bowen et al. 1998).  
The overall numbers of myeloid cell lineages vary and morphological aberrations are 
observed in the clonal origin of hematopoietic cells.    Hypercellular bone marrow displays 
morphological dysplasia and ineffective hematopoiesis in at least one of the three myeloid 
lineages (Aul, Bowen et al. 1998, Tefferi, Vardiman 2009, Whichard, Sarkar et al. 2010).  
Cellular bone marrow is unable to produce and deliver adequate numbers of mature cells 
to the peripheral blood during ineffective hematopoiesis.   
Even though MDS is predominantly a disease of older populations, the frequency 
in the pediatric and young adult population, or those between the ages of 0 and 29, is 
slowly on the rise.  Myelodysplastic syndromes in pediatric cases present diverse 
cytogenetic findings and differs in OS in comparison with the elderly.  The amount of 
information on this rare group is limited.  In order to aid in therapeutic stratification for 
pediatric patients more information is needed (Glaubach, Robinson et al. 2014, Ganapathi, 
Schafernak et al. 2015) .  The use of high-resolution techniques including microarray can 
help with deciphering possible key aberrations that are observed at the genetic level.  
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Current molecular genetic studies have detailed key genes involved in adult MDS and the 
present study will be useful to compare similarities and differences between the elderly 
and pediatric populations (Silva, Maschietto et al. 2013, Shih, Abdel-Wahab et al. 2012, 
Bejar 2014).  
The onset of this disease can be relatively benign in the form of refractory anemia 
(RA), typically observed as a decrease in red blood cells, but causes a decrease in the 
production of healthy platelets, red and white blood cells (Aul, Bowen et al. 1998, Tefferi, 
Vardiman 2009, Corey, Minden et al. 2007, Akhtari 2011).  Red blood cells (RBC) transport 
oxygen to the rest of the body and brings carbon dioxide to the lungs.  Having too few 
RBC, anemia, leaves the patient feeling tired and weak and can cause shortness of 
breath.  White blood cells (WBC) are important as a line of defense against infection.  The 
two major types are lymphocytes, which make antibodies, and granulocytes that destroy 
bacteria.  Having too few WBC leads to severe infections in the body, or neutropenia.  The 
small fragments of the megakaryocyte that enter the blood stream are called platelets.  
These are essential for blood clotting and without them can result in thrombocytopenia, 
which causes abnormal bleeding, and bruising (Brunning, RD. Bennett, JM. Flandrin, G. 
Matutes, E. Head, D. Vardiman, JW. 2001).   
Myelodysplastic syndromes can be diagnosed as primary, or de novo MDS, or 
secondary MDS from past chemo- or radiation therapy or exposure to certain chemicals 
and heavy metals.  Both result in dysplastic blood and bone marrow cells and cytogenetic 
abnormalities are observed in over 50% of MDS cases (Corey, Minden et al. 2007, 
Flandrin 2002).  Hallmark genetic aberrations detected by conventional karyotyping or 
fluorescence in situ hybridization (FISH) include -5/del(5q), -7/del(7q), +8, or del(20q) 
(Cherian, Bagg 2006).  The classification of these genetic findings has prognostic 
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implications and helps to stratify a more individualized treatment plan for MDS patients 
(Haase, Germing et al. 2007).   
Hematopoiesis 
Normal hematopoiesis gives rise to progressively more differentiated progenitor 
cells, which eventually differentiate into mature blood cells (Lobo, Shimono et al. 2007, 
Orkin, Zon 2008).  The fundamental properties of hematopoiesis include proliferation, loss, 
and differentiation resulting in the development of over 500 billion blood cells per day.  
Normal adult hematopoietic stem cells (HSCs) are the common ancestors of all blood cells 
and are needed to maintain or repair their host tissue.  These cell types have two functions 
of division that include symmetrical division, which yields two stem cells or two 
differentiated daughter cells, and asymmetrical division into either another stem cell or a 
more specialized cell.  Self-renewal of HSCs produces a replicate stem cell that typically 
has the same development and replication fate.  The production of specialized daughter 
cells is decided from biochemical signals and transcription factors and the HSC has the 
potential to generate cell types of each lineage (Kondo 2010, Whichard, Sarkar et al. 2010, 
Wilson, Laurenti et al. 2008).   
During normal hematopoiesis the blood stem cell, or immature blast cells, make 
up 5% or less of the cells in the bone marrow and will develop into one of the three healthy 
blood cells (red blood cells, platelets, or white blood cells) from a homeostatic balance 
between proliferation, differentiation, and apoptosis (Figure 1a).  The normal system 
efficiently replenishes the body when hematological stresses are encountered which 
includes infection and blood loss (Passegue, Wagers et al. 2005).  Hematopoietic 
disorders, including MDS, are acquired when normal development is disrupted and blast 




   




















































































































































































































































































































































































entering the blood.  Cellular bone marrow is then unable to produce and deliver adequate 
numbers of mature cells to the peripheral blood.  Ineffective hematopoiesis presents a 
loss of homeostatic balance between proliferation, differentiation, and apoptosis leading 
to cell death of many precursor cells giving an overall unbalance in cell production.  A 
varying degree of cellular dysplasia and an overall reduction in RBC, platelets, and WBC 
is produced (Figure 1b).  This results in a higher propensity of infection, anemia, bleeding 
and the evolvement to acute myeloid leukemia (AML) (Corey, Minden et al. 2007, Tefferi, 
Vardiman 2009, Akhtari 2011).   
Pathogenesis of MDS 
Even though morphological variation exists, the clonal disorder of MDS progresses 
through the same multistep process of tumorigenesis of initiation, promotion, and 
malignant transformation.  A single or even multiple initial genetic insults occur to the 
predominantly quiescent HSCs and initiates the cell into an early lesion state (Wilson, 
Laurenti et al. 2008, Fozza, Longinotti 2013).  The exact nature of the initial insult has yet 
to be deciphered.  Promotion or progression of the abnormal clones occur with abnormally 
high rates of apoptosis on the normal cells and leads to transformation.  The 
transformation stage has an apoptotic paradox of excessive cell death during initiation and 
promotion stages followed by a loss of apoptotic function that increases cell survival and 
proliferation of malignant cells.  Over time, MDS has the ability to progress to a malignant 
transformation and ultimately evolve to AML (Davids, Steensma 2010, Kulasekararaj, 
Mohamedali et al. 2013).   
Initiation and Promotion 
The cancer stem cell theory originated from studies showing that some aspects of 
normal cell growth and differentiation are observed in tumor growth.  Malignant cells arise 
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from long-lived stem cells with the capability of self-renewal but unlike normal expansion, 
uncontrolled growth is not prevented (Lobo, Shimono et al. 2007).  It was once believed 
that cancer stem cells were derived from normal stem cells but new studies show that 
progenitor cells can also gain normal stem cell attributes of long life and self-renewal.  
Leukemic stem cells have been shown to originate from progenitor cells with additional 
mutations that gives them the ability to self-renew.  A single or multiple initial genetic insult 
event to either type of stem cell leads to the tumor promotion stage of clonal expansion of 
abnormal clones.  These clones have abnormally high rates of apoptosis downstream in 
later progenitors due to their longevity and therefore their ability to accumulate genetic 
changes (Wang, Dick 2005, Chatterjee, Choudhry 2013).   
The exact mechanism for tumorigenesis is still unknown but many studies have 
suggested that the microenvironment plays a role (Raaijmakers 2012).  The 
microenvironment of bone marrow elements has been shown to be disorganized and all 
lineages in MDS patients can become affected.  These elements subject stem cells to a 
range of stimuli including cell-cell interactions, contact to extracellular matrix molecules, 
and exposure to growth stimulatory and inhibitory cytokines.  These growth factors not 
only stimulate proliferation but also support cell survival, and their loss presents an 
increase in apoptosis (Arai, Hirao et al. 2005, Aul, Bowen et al. 1998).  Mutations of the 
genes within the stem cell niche causes failure of bone marrow stem cell maintenance 
and a thorough understanding of these aberrations can aid in potential targeted therapies 
for MDS patients (Wilson, Trumpp 2006).    
Transformation 
After the stages of initiation and promotion, MDS can then progress to a malignant 
transformation increasing the amount of leukemic blast cells and ultimately evolving to 
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AML.  Clonal expansion of MDS show changes of dysplasia, ineffective hematopoiesis, 
cellular dysfunction, and defective differentiation (Aul, Bowen et al. 1998).   
Dysplasia in MDS can lead to morphological changes of the immature blast cell, 
which leads to changes in colony formation and the ability to produce a healthy adherent 
cell layer.  Poor colony formation results in an abnormal increase in cluster formation.  
Dysplasia from MDS also causes abnormal megakaryopoiesis, or platelet production, 
which leads to the presence of micromegakaryocytes, small platelet precursors.  These 
are associated with large atypical platelets and is often associated with myeloproliferative 
disorders (MPD) (Howe, Porwit-MacDonald et al. 2004, Sun, Konoplev et al. 2011, Orazi, 
Germing 2008). 
In ineffective hematopoiesis, apoptosis and cell death of many cell precursors 
occurs, limiting production of healthy blood cells.  Furthermore, increased cell proliferation 
concurrently with reduced cell differentiation leads to a net increase in the number of 
precursor cells despite higher rates of apoptosis (Ginzburg, Rivella 2011).  Mutations in 
cell division and signaling systems that regulate specialization leads to abnormal 
proliferations and typically results in the aberrant cell being eliminated but cancers can 
occur when these mutations escape destruction and accumulate.  Typically, short-lived 
cells, like differentiated progeny, are less prone to these mutations in comparison to the 
longer-lived stem cell populations (Lobo, Shimono et al. 2007).   
Cellular dysfunction has been attributed to the progression of abnormal MDS 
clones slowly replacing normal stems cells through excessive apoptosis.  Defective 
maturation including delayed maturation leads to an increase in non-erythroid lineages 
and an increase in early myeloid cells.  In spite of normal and hypercellular bone marrow, 
persistent premature cell death has been shown in bone marrow biopsies.  Numerous 
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DNA breaks and increased engulfment by macrophage has been observed in bone 
marrow and leads to an ineffective production of red blood cells and the suppression of 
normal stem cell differentiation (Aul, Bowen et al. 1998).  In some MDS subtypes, cytotoxic 
T-cells have been found to be the primary inhibitor of hematopoietic precursors by 
increasing the frequency of apoptosis (Fozza, Longinotti 2013).  Malignant transformation 
of MDS to AML is caused from an apoptosis paradox.  The excessive cell suicide during 
initiation and promotion stages, now leads to the uncontrolled growth of malignant cells 
with increased cell survival and proliferation.   Cells from AML cases have been shown to 
contain significantly reduced apoptotic behaviors especially when certain chromosome 
aberrations are present.  For example, in 5q deletions, tumor aggressiveness is increased 
through the inactivation of the tumor suppressor gene IRF-1 found in the 5q critical region 
which has been attributed to the reduction or complete loss of apoptotic function 
(Pitchford, Hettinga et al. 2010, Mallo, Arenillas et al. 2008, List, Dewald et al. 2006, Aul, 
Bowen et al. 1998).   
Lastly, defective differentiation suppresses normal stem cell differentiation.  
Normal differentiation uses unique hematopoietic cells that are able to self-renew as well 
as generate all cells of the hematopoietic system.  They give rise to multipotent progenitors 
and lineage-restricted progenitors that have a limited capacity to divide.  On the other 
hand, leukemic stem cells have been hypothesized to originate from immature 
hematopoietic progenitors or even the HSC and will give rise to clonogenic leukemic 
progenitors that differentiate into leukemic blasts and more differentiated progeny (Tan, 
Park et al. 2006).   
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Epidemiology of MDS 
The onset of MDS can be relatively benign in the form of refractory anemia and 
can show signs of fatigue, shortness of breath, pale skin, and easy bruising or bleeding.  
Diagnosis of MDS consists of blood and bone marrow tests.  Lower than usual numbers 
of red blood cells, neutrophils, and platelets is frequently seen in MDS.  Bone marrow 
aspirates are biopsied and sent for more extensive genetic tests and diagnosis of MDS 
occurs when an excessive amount of blast cells are present, chromosomal abnormalities 
typical for MDS are observed, and/or changes in the structure or form of the bone marrow 
cells (Brunning, Bennett, et al. 2001, Cherian, Bagg 2006). 
Myelodysplastic syndromes are typically described as a geriatric disorder due to 
the gradual accumulation of random genetic damage from endogenous and exogenous 
carcinogens over a lifetime.  The risk of MDS increases with age; 3.5 to 12.6 adults per 
100,000 over the age of 60; 15 to 50 per 100,000 over 70 years; and 89 per 100,000 for 
the over 80 populations with men having a slightly higher risk than women with a 1.2 ratio 
(Corey, Minden et al. 2007, Rollison, Howlader et al. 2008).  As of 2014, the estimates 
from Medicare claims show that MDS is one of the top 10 adult neoplasms with at least 
40,000 to 50,000 patients per year being diagnosed (Steensma, Komrokji et al. 2014, 
Goldberg, Chen et al. 2010).  
Even though MDS is one of the most prevalent bone marrow disorders in the older 
populations; it is less frequently diagnosed in those under the age of 29 years. The 
incidence in the pediatric population, or those between the ages of 0 and 18, is 1.8 to 4 
cases of MDS per million children per year (Rau, Shreedhara et al. 2012, Hofmann 
2015a).  Since this malignancy is less frequently observed, there is limited information 
regarding the diagnostic criteria for MDS in the younger population and in turn even less 
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information on the specific subtypes and prognostic implications in this group (Glaubach, 
Robinson et al. 2014, Hofmann 2015b).   Younger patients presenting MDS are on the 
rise and typically present diverse features in comparison to the adult population including 
a more unfavorable prognosis and a higher propensity to evolve to malignant neoplasms 
including AML (Aul, Bowen et al. 1998, Tefferi, Vardiman 2009, Corey, Minden et al. 2007, 
Akhtari 2011, Mandel, Dror et al. 2002, Hofmann 2015a, Gohring, Michalova et al. 2010).  
Until the 2003 World Health Organization (WHO) Pediatric modification, children were 
categorized with the adult population.  This was due to the limited information on any real 
differences between the two populations that resulted in the younger population receiving 
the same treatments and similar therapy strategies were utilized as in the older population 
(Hasle, Niemeyer et al. 2003).   
With limited cases and a lack of consensus on when to diagnose MDS in pediatric 
patients, classifying new and individualized diagnostic and prognostic criteria for these 
individuals was quite difficult.  With more research, some key differences between the 
adult and pediatric MDS populations have been determined.  Refractory anemia with ring 
sideroblasts is quite common in adults and is very rare in younger patients and isolated 
anemia is one of the major presentations in adults while thrombocytopenia (TCP) and 
neutropenia (NEU) are the major presentations in pediatric populations (Chatterjee, 
Choudhry 2013). The most frequent cytogenetic abnormality of isolated deleted 5q 
observed in the adult population is rarely seen in pediatric MDS.  In addition, the median 
age of MDS presentation in adults is 70 with primary MDS being the most common while 
in the pediatric population the median age is 7 years and the most common type is 
secondary or therapy-related MDS (Glaubach, Robinson et al. 2014, Niemeyer, Baumann 
2008).   
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Since the etiology of MDS has been linked to age related alterations, including 
certain epigenetic factors like methylation, criteria on the vast number of older patients 
with this disease is understood (Shih, Abdel-Wahab et al. 2012).  The reasons for 
occurrence of MDS in pediatric and young adult patients, or those between 0 and 29 years 
of age, has yet to be fully understood.  Studies show a strong correlation to certain genetic 
disorders that are associated with a future MDS occurrence including trisomy 21 (Down 
syndrome), Fanconi’s anemia, and inherited bone marrow failure disorder; yet biological 
and clinical features are different in non-Down children with MDS and not all pediatric MDS 
patients have one of these constitutional disorders (Rau, Shreedhara et al. 2012, Stary, 
Baumann et al. 2008, Glaubach, Robinson et al. 2014, Cantor 2015).  Therefore, more 
research is needed in order to decipher what triggers the ineffective hematopoiesis.  When 
we can accurately diagnose and determine the true characteristics of pediatric MDS, we 
will then be able to prepare a more individualized therapeutic strategy for the younger 
population. 
Classification of MDS 
Currently, MDS in the pediatric and adolescent populations is classified as either 
primary MDS, or de novo MDS, and secondary MDS (Rau, Shreedhara et al. 2012).  
Primary MDS is subdivided into refractory cytopenia of childhood (RCC), refractory 
anemia with excess blasts (RAEB) and RAEB in transformation (RAEB-t) (Niemeyer, 
Baumann 2011).  Diagnosis is typically determined by morphological criteria, karyotype 
analysis, and molecular genetic techniques.  These tests help in risk-assessment and 
determining the most effective therapeutic approaches (Aul, Bowen et al. 1998, Stary, 
Baumann et al. 2008).     
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Refractory Cytopenia of Childhood (RCC) 
The most common pediatric and young adult subtype of primary MDS is RCC and 
can be difficult to distinguish from other disorders due to the overlapping morphological 
findings, which includes a variety of viral infections, vitamin deficiencies, and metabolic 
disorders.  This subtype is seen in more than half of the childhood MDS cases and affects 
both males and females equally.  These patients frequently present thrombocytopenia and 
neutropenia with a hypocellularity of bone marrow cells occurring in 75% of the patients 
and less frequently presents anemia.  Refractory cytopenia of childhood affects the bone 
marrow and blood and is rarely observed in the lymph nodes, spleen, or liver (Germing, 
Aul et al. 2008, Chatterjee, Choudhry 2013).  The most common signs and symptoms of 
RCC in children are malaise, bleeding, infection, and fever with over 20% of cases being 
asymptomatic.  Less than 2% blasts are found in the peripheral blood and less than 5% in 
the bone marrow.  Bone marrow aspirates present dysplastic changes including non-
lobulated nuclei, micromegakaryocytes, and abnormally separated nuclear lobes with an 
increase in erythropoiesis resulting in increased numbers of mitoses (Koh, Cho et al. 
2013).  Most RCC bone marrow aspirates will show a normal karyotype or a loss of 
chromosome 7 as the most common abnormality but karyotypes that are more complex 
have also been observed.  Cytogenetic karyotyping is the most important tool to determine 
the progression of RCC into more advanced subtypes of MDS.  The consequence of loss 
of chromosome 7 has an increased chance of progression than a normal karyotype or 
other aberrations with a median progression time of 1.9 years.  A gain of chromosome 8 
or a normal karyotype may result in longer OS and represents a more stable disease.  
Hematopoietic stem cell transplant (HSCT) is the treatment of choice in the early stages 
of RCC when monosomy 7 or a complex karyotype is observed and presents a favorable 
OS after treatment.  Immunosuppressive therapy (IST) is a potential treatment for patients 
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with infections, presenting severe cytopenia, or lack the appropriate transfusion 
requirements from T-cell immunosuppression of hematopoiesis (Niemeyer, Baumann 
2011, Chatterjee, Choudhry 2013).      
Refractory Anemia with Excess Blasts and Refractory Anemia with Excess 
Blasts in Transformation (RAEB and RAEB-T) 
Refractory anemia with excess blasts, also called oligoblastic myelogenous 
leukemia, consists of 2-19% blasts in the peripheral blood or 5-19% blasts in the bone 
marrow.  In children, RAEB is typically slow progressing and shows stable blood counts 
for extended periods (Greenberg, Cox et al. 1997).  Refractory anemia with excess blasts 
in transformation may behave more like MDS and lacks the typical clinical features of AML 
including the responses to AML-type therapies (Chatterjee, Choudhry 2013).  An 
increased number of blast cells at about 20 to 30% are observed in the bone marrow in 
RAEB-T.  Typically, RAEB and RAEB-t present with AML associated cytogenetic 
aberrations of t(15;17), t(8;21), inv(16), t(9;11), or complex karyotypes consisting of three 
or more aberrations (Hasle, Niemeyer et al. 2003).  This subtype is the interface between 
MDS and de novo AML.  The most appropriate treatment for RAEB and RAEB-t is 
unknown but hematopoietic stem cell transplantation can increase overall survival of the 
patient (Chatterjee, Choudhry 2013, Hasle, Niemeyer et al. 2003).   
Secondary MDS: Treatment Related and Occupational Exposure 
Secondary MDS occurs at a younger onset age after chemotherapy or radiation 
therapy for a prior disease, after acquired aplastic anemia, or as a result of an inherited 
bone marrow failure disorder (IBMF) or familial disease (Niemeyer, Baumann 2011, Hasle, 
Niemeyer et al. 2003).  The exposure to chemotherapeutic alkylating agents following 
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treatment for Hodgkins lymphoma (HL), Non-Hodgkins lymphoma (NHL), and acute 
lymphoblastic lymphoma (ALL) have been shown to be related to secondary MDS in 
younger populations (Stone 2009, Armitage, Carbone et al. 2003, Rubin, Arthur et al. 
1991).  The damage to hematopoietic stem cells during drug therapy causes an increase 
in the frequency and severity of thrombocytopenia, increases AML transformation, and 
decreases OS.  Ionizing radiation effects leukemia progression but is dose and duration 
dependent.  For example, the total dose exposure in HL treatment is directly proportional 
to the development of secondary MDS (Aul, Bowen et al. 1998).    
Occupational and environmental carcinogens including heavy metals, fumes, 
exhaust gases, pesticides and cigarette smoking can lead to secondary MDS.  
Occupational exposures are less observed in the younger populations than the adult 
population but include exposures to copper, welding fumes and hydrogen peroxide.  Other 
potential occupational causes of MDS later in life include associations with degreasing 
agents, nickel, exhaust gases and radio transmissions (West, Stafford et al. 2000).  In 
smaller case-controlled studies, plant and machine operation exposures to pesticides, 
exhaust fumes, fertilizers, and store dust have implicated etiologies for secondary MDS.  
Another risk for MDS includes cigarette smoking due to the number of carcinogens, 
specifically the presence of benzene (West, Stafford et al. 2000).  Benzene has been 
shown to cause a high incidence of morphological dysplasia and severity of 
thrombocytopenia, increases AML transformation, and decreases OS.  Benzene in the 
workplace including petroleum plants has stricter laws lowering the amount of benzene 
exposure due to the negative effects later in life (Aul, Bowen et al. 1998).   
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Inherited Bone Marrow Failure Disorders (IBMF) 
Inherited bone marrow failure disorders have overlapping morphological features 
with RCC including macrocytosis of the red blood cells on blood smears and elevated 
hemoglobin F.  These disorders need to be excluded using extensive past medical and 
family history evaluations in order to differentiate between IBMF and RCC (Niemeyer, 
Baumann 2011).  These acquired bone marrow disorders only consist of a small fraction 
of MDSs in the population.  Familial MDSs come from hereditary disorders that cause 
defective DNA repair and include Fanconi’s anemia and Bloom’s syndrome.  Fanconi’s 
anemia begins in childhood with bone marrow failure; 4-7% progress to MDS and AML in 
childhood and over 40% progress by the age of 40.   
Cytogenetically, these patients typically present monosomy 7 or gain of 3q26, 
which has been shown to have an adverse risk factor for AML progression due to the 
overexpression of EVI1 (Bernasconi, Cavigliano et al. 2003, Seif 2011, Niemeyer, 
Baumann 2011).  On the contrary, a gain of chromosome 1q, observed cytogenetically 
can lead to an extended amount of years without progression.  Neurofibromatosis, a 
genetic disorder of the nervous system, Shwachman-Diamond syndrome (SDS), and 
Down syndrome have also been attributed to MDS.  Patients with SDS have a 10-25% 
risk of MDS progression and cytogenetically show an increase in the incidence of 
isochromosome 7q leading to a potential clonal marker for the SDS in the SBDS gene 
located at 7q11.2 (Cantu, Proytcheva 2015).  Fortunately, cytogenetic correlations have 
shown a stable course for many years with i(7q) or del(20) in SDS patients (Chatterjee, 
Choudhry 2013, Niemeyer, Baumann 2011).   
An association with Down syndrome is seen in 20-25% of the pediatric MDS cases 
and these patients have a 10 to 20-fold increased risk of AML progression in comparison 
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to non-Down syndrome patients.  However, this type of myeloid leukemia is unique to this 
population and is classified into its own category of myeloid leukemia of Down syndrome 
(ML-DS) (Chatterjee, Choudhry 2013, Germing, Aul et al. 2008, Seif 2011, Cantor 2015).   
Aplastic Anemia (AA) 
Aplastic anemia (AA) displays aplasia of all three hematological cells with an 
increase in lymphocytes, plasma cells and mast cells.  This form of anemia has been 
shown to have an immune-mediated pathogenesis and typically follows 
immunosuppression with antithymocyte globulin, an antibody administered against human 
T-cells for drug therapy (Fu, Xue et al. 2015).  These agents have an incidence of MDS 
evolution at 9.6% and those that evolve to MDS typically display monosomy 7 or trisomy 
8 by conventional cytogenetic analysis (Aul, Bowen et al. 1998, Niemeyer, Baumann 2011, 
Ohara, Kojima et al. 1997).   
Treatment for MDS 
The only potential cure for MDS consists of allogenic HSCT.  The goals of the 
transplant are to restore the body’s ability to make healthy blood cells once chemotherapy 
has been administered and to kill any remaining MDS cells.  When benefits exceed the 
risks for the patient, this in an option when a stem cell donor is available.  Unfortunately, 
HSCT is not a favorable therapy in the older populations due to the dangers of advanced 
age and other comorbidities (Tilak, Sookmane et al. 2008, Smith, Christiansen et al. 2013). 
The current treatment of MDS primarily in the elderly populations includes the use 
of one of three FDA approved chemotherapeutic drugs azacitidine, decitabine, and 
lenalidomide (Zou, Fink et al. 2007, List, Dewald et al. 2006).  These drugs are approved 
for both low- and high-risk patients.  In the adult populations, MDS has well recognized 
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entities including cytogenetic findings that result in specific treatments and therapy 
(Giagounidis 2006).  For example, the most frequent cytogenetic abnormality in the adult 
population, about 30% of the abnormal adult MDS cases, consists of loss of chromosome 
5 or more frequently the loss of the long arm of 5 and the hypomethylating agents of 
azacitidine and decitabine are approved and used for these patients with a high success 
rate.  Without the observance of a complex karyotype, this treatment gives the most 
favorable prognosis for survival with a higher median year of OS (Greenberg, Tuechler et 
al. 2012, Haase 2008, Haase, Germing et al. 2007, Steensma, Komrokji et al. 2014).  
Unfortunately, these same therapies have yet to be deemed as a successful 
treatment in the pediatric population; without a bone marrow transplant, OS of pediatric 
MDS patients is low (Ohara, Kojima et al. 1997, Silva, Maschietto et al. 2013, Steensma, 
Komrokji et al. 2014).  Since HSCT is the most favorable treatment for patients with less 
advanced age, it is ideal for the pediatric MDS population.  This treatment is most 
successful when performed early in the disease and is one reason why an accurate and 
timely diagnosis criterion needs to be established.  The sooner we can diagnose, the 
sooner we can treat, and the higher probability that a cure can occur (Germing, Aul et al. 
2008, Smith, Christiansen et al. 2013).  With the numerous techniques currently available, 
it is crucial to continue to contribute to the scientific understanding of pediatric MDS, so 
early diagnostic testing is made available.     
Genetic Testing in Myelodysplastic Syndromes 
The heterogeneity of MDS is not only observed in cellular morphology but is also 
seen at the genetic level.  Cytogenetic abnormalities by conventional karyotyping or FISH 
is observed in over 50% of MDS cases; yet a single cytogenetic abnormality is not 
considered a genetic hallmark of the disease (Haase, Germing et al. 2007, Cherian, Bagg 
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2006, Rigolin, Bigoni et al. 2001).  Variable abnormalities including the hallmark 
cytogenetic abnormalities for adult MDS of monosomy 5 or a del(5q), monosomy 7 or 
del(7q), trisomy 8, and del(20q) are described in MDS (Haase 2008, Pitchford, Hettinga 
et al. 2010).  Cytogenetic techniques are an essential tool in accurate diagnosis and 
provide important prognostic impact including therapeutic stratification.  These strategies 
are used for determining disease clonality and to determine probabilities of AML 
progression (Costa, Valera et al. 2010, Bernasconi, Cavigliano et al. 2003, Valent, Horny 
2009).  The presence or absence of specific aberrations form the basis of very good-, 
good-, intermediate-, poor-, or very poor-prognosis designation in the adult population 
which has a profound impact on patient survival and leukemic transformation (Germing, 
Aul et al. 2008, Greenberg, Tuechler et al. 2012).    
Cytogenetic abnormalities of MDS typically consist of an unbalanced aberration in 
the form of deletions or monosomies leading to the assumption that tumor suppressor 
genes have lost function or have become inactivated.  Balanced translocations and 
inversions along with random abnormalities are rarely observed.  The presence of 
hallmark aberrations, either as a sole anomaly or in a more complex karyotype with more 
than one change, contributes to the overall prognostic score.  The occurrence of these 
abnormalities have shown distinct differences between the adult and pediatric 
populations.  To date, we have already determined distinct features in the pediatric 
population that are different from the adult patients including the occurrence and frequency 
of these hallmark cytogenetic abnormalities and their prognostic implications.  Refinement 
of the prognosis of chromosomal findings has occurred as recently as 2012 in the revised 
international prognostic scoring system (IPSS-R) and provides insight into the patient's 
OS and the frequency of MDS transformation into AML (Greenberg, Tuechler et al. 2012, 
Kulasekararaj, Mohamedali et al. 2013, Gohring, Michalova et al. 2010, Greenberg 2015). 
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Cytogenetics in Adult Populations 
The most frequent cytogenetic abnormality among the adult population, over 30%, 
consists of the loss of chromosome 5 or a variable deletion of the long arm of chromosome 
5 (-5/del5q) but always spanning the chromosome region of q31 (Haase, Germing et al. 
2007).  This abnormality presents the most favorable prognosis in the older populations 
with specific therapies and treatments that present favorable OS.  The least favorable 
prognosis occurs with the loss of chromosome 7 or a deletion of the long arm of 7 (-7/ 
del7q) and is observed in about 21% of adult MDS (Jhanwar 2015).  Loss of 7 or del(7q) 
occurs more often as part of a complex karyotype and is associated with severe refractory 
cytopenia and a proneness to infections.  Drug therapy for these patients has been 
unsatisfactory and the best treatment is allogeneic stem cell transplantation, when 
possible (Deeg, Scott et al. 2012).  Trisomy 8 (+8) in the adult population is only observed 
in about 16% of MDS and is observed as a sole anomaly 46% of the time.  This abnormality 
falls under an intermediate prognosis of a median month of survival at or above 23 months 
(Haase 2008).  A deletion of the long arm of chromosome 20 (del20q) is the least frequent 
abnormality observed at about 7% and gives a favorable prognosis of OS above 23 
months (Haase 2008, Haase, Germing et al. 2007, Mallo, Arenillas et al. 2008).   
Cytogenetics in Pediatric Populations 
In the pediatric population, 55% of the primary MDS cases contain a karyotypic 
abnormality and 76% of the secondary MDS cases contain an abnormality that can be 
observed using conventional techniques (Gohring, Michalova et al. 2010, Silva, 
Maschietto et al. 2013).  The differences between the adult and younger populations is 
seen in the occurrence and frequency of hallmark cytogenetic abnormalities.  The most 
distinct difference between the adult and pediatric population occurs with the hallmark 
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abnormality of -5/del(5q).  In the pediatric population, -5/del(5q) is virutally never seen, 
and when observed, presents the most unfavorable prognosis  (Hofmann 2015a).  The 
younger patients with this aberration have the highest occurrence of AML transformation, 
a lowered OS, and the treatment protocol remains undefined.   
The pediatric MDS population exhibits -7/del(7q) most frequently amongst the four 
hallmark abnormalities in about 30% of the patients (Niemeyer, Baumann 2008, Kardos, 
Baumann et al. 2003).  This chromosomal aberration is seen as a sole abnormality, 
presents the most favorable prognosis in young patients, and correlates with a longer-
term survival.  The moderate frequency, 16%, of a +8 in the younger population is 
comparable to the frequency observed in the adult population.  In both populations, this 
abnormality falls under an intermediate prognosis of a median month of survival at or 
above 23 months.  Lastly, the observance of del(20q) in the pediatric population is 
comparable to the adult population in about 10%.  This abnormality presents a prognosis 
of survival above 23 months in both populations (Glaubach, Robinson et al. 2014, Rau, 
Shreedhara et al. 2012).    
Prognostic Implications of Cytogenetics 
According to the most recent IPSS-R, prognostic variables are given scores based 
upon the number of blasts in the bone marrow, number of platelets, absolute neutrophil 
count, hemoglobin numbers, and cytogenetic findings.  Cytogenetic findings are needed 
to determine specific anomalies and the number of aberrations present to determine the 
prognostic implications for MDS (Steensma, Komrokji et al. 2014).  The score values for 
these factors will predict median survival in years without treatment and the potential of 
AML transformation without therapy.  A prognostic score value of very good, good, 
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intermediate, poor, and very poor is given for specific cytogenetic abnormalities being 
observed.   
In adult MDS cases, a score of ‘very good’ is given to MDS cases with a loss of 
the Y chromosome (-Y) and a deletion of the long arm of chromosome 11, del (11q).  The 
loss of Y aberration has often been associated with advanced age in males.  
Myelodysplastic syndrome is typically a disease of the advanced age, hence loss of Y 
would be common in MDS and prognostic correlations show that it leads to a favorable or 
neutral prognosis (Goldberg, Chen et al. 2010, Flandrin 2002).  A score of ‘good’ is given 
with normal karyotypes, del(5q), del(12p), del(20q), and double abnormalities with del(5q).  
Cytogenetic findings of del(7q), +8, +19, i(17q), and the presence of any other single or 
double independent clones leads to an ‘intermediate’ score.  A ‘poor’ score consists of -7, 
inv(3)/t(3q)/del(3q), double abnormalities including -7/del(7q), and complex karyotypes 
with three abnormalities.  A ‘very poor’ score is given to adult MDS cases with more than 
three cytogenetic abnormalities (Greenberg 2015, Greenberg, Tuechler et al. 2012).  
 In general, these prognostic scores are meant as a point of reference for MDS 
cases and caution should be used when pediatric management and therapeutic strategies 
are utilized.  Even though the IPSS is a useful therapy guide in adults, a validated and 
useful prognostic guide for the pediatric group has not been established to date and is 
needed for therapeutic success in this group of patients.   
Utility of Microarray Studies 
Understanding the genetic characteristics unique to the pediatric group is the first 
step to decipher the unknowns in this group of MDS.  Conventional techniques are able 
to detect chromosomal abnormalities in over 50% of primary MDS and 80% of secondary 
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MDS cases but in order to detect aberrations that may be too small or that are missed by 
these techniques; we need to utilize higher resolution array techniques.  This technique is 
a reliable and efficient tool to identify genomic alterations in MDS from bone marrow DNA 
(Maciejewski, Tiu et al. 2009).  When deletions and gains are observed cytogenetically, 
this suggests haplosufficiency, a loss of tumor suppressor genes, or oncogene activation 
and microarray can shed light onto these molecular alterations.   
Microarray will also be useful in suboptimal cases with little or no growth of cells 
and for those studies that present normal karyotypes and FISH analyses (Visconte, Selleri 
et al. 2014).  With rare diseases that have limited information, we are in need of a starting 
point and we can achieve this through the utilization of resources and techniques that are 
available to us.  Copy number variations (CNV), microdeletions and single-nucleotide 
polymorphisms (SNPs), and specific gene disruptions that alter epigenetic regulators can 
be detected using microarray techniques.  High-resolution microarray can improve the 
detection of genomic aberrations in MDS by identifying key alterations in copy number 
gains or losses in DNA from MDS samples.  Microarray studies do not require 
chromosome preparations to determine copy number changes and they can identify very 
small deletions and duplications that would otherwise be undetected by conventional 
cytogenetic techniques (Silva, Maschietto et al. 2013, Ismael, Shimada et al. 2012).   
Current novel studies have determined that the majority of adult MDS patients, 
over 80%, have a detectable somatic alteration among genes involved in various 
epigenetic regulatory pathways (Shih, Abdel-Wahab et al. 2012, Bejar 2014).  Over 60 
genes have been identified and play a role in chromatin modification, DNA methylation, 
transcriptional regulation, DNA repair/tumor suppressor, signal transduction, and 
cohesion complexes.  RNA splicing mutations play a major role in determining clinical 
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features of the disease including the morphological features and OS of the patient (Zhang, 
Padron et al. 2015, Jhanwar 2015, Greenberg 2015, Visconte, Selleri et al. 2014, 
Papaemmanuil, Gerstung et al. 2013).  However, these somatic mutations have yet to be 
included into the current prognostic scoring systems and most studies detailing these 
genetic changes have been conducted on adult MDS cases.  The continued identification 
of key genes is a crucial step in deciphering players involved in hematopoietic 
transformation in the pediatric MDS group.  This information can be used to better equip 
the medical community in accurately diagnosing and providing prognostic implications for 
therapy and treatment (Bejar 2014).  
Hypothesis and Specific Objectives 
Since MDS is less frequently observed in the younger populations, there is limited 
information available in comparison to the elderly population including diagnostic criteria 
and prognostic implications.  The younger population is relatively less exposed to the 
environmental and occupational risk factors, and for a shorter time span, therefore, it is 
more likely that a genetic alteration may be playing a role in disease causation.   
Genetic disorders are closely associated with a predisposition to MDS including 
Down syndrome, Bloom syndrome, and IBMF syndromes but not all pediatric MDS 
patients share one of these constitutional syndromes.  More research is needed in order 
to decipher the genetic causes of the disease.  Our overall working hypothesis is that there 
are distinct genetic differences between pediatric/young adult and elderly MDS 
populations; and in-depth investigations can improve the understanding of the 
pathophysiology, refine diagnostic categorization and therapeutic stratification using 
comprehensive analysis of multiple genetic techniques.  
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Inconsistence and imprecise classification of pediatric MDS causes differences in 
the diagnosis and reporting of this rare group.  We propose to perform cytogenetic 
comparisons in pediatric/young adult and adult/elderly MDS samples. A comprehensive 
genetic analysis using microarray in a subset of pediatric/young adult MDS cases will be 
conducted.  The significance of altered genes in various pathways will be determined.  
This study uses one of the largest cytogenetically characterized cohorts of MDS 
specimens in order to accurately detect frequencies of specific abnormalities.  A small 
subset of pediatric/young adult cases will be used for high-resolution array studies to 
determine cryptic abnormalities not observed by conventional cytogenetic techniques.  A 
comparison to existing reports helps determine the genomic alterations that specifically 
influence the classification and pathway changes in MDS cases.  Even though current 
studies have determined a set of recurrent abnormal gene aberrations in MDS cases, the 
vastly different populations of adult and pediatric has not been well characterized at the 
molecular level (Papaemmanuil, Gerstung et al. 2013, Zhang, Padron et al. 2015).   
Currently, there are no known targeted therapies based upon the genetic 
landscape in the younger populations.  This study will give insight on any differences and 
similarities between MDS from the two age groups and will allow us to better understand 
the key genetic and prognostic differences that can subsequently aid in the development 































MATERIALS AND METHODS 
This study was comprised of conventional cytogenetics, FISH, and Affymetrix 
CytoScan® or OncoScan® array analysis of MDS specimens that were referred to the 
Human Genetics Laboratory at the University of Nebraska Medical Center from January 
1, 2003 to December 31, 2015.  Bone marrow aspirations and unstimulated peripheral 
blood samples were used for cytogenetic and FISH analyses and when available, DNA 
was extracted from leftover whole specimen for microarray analysis.  This study was 
approved by the institutional review board. 
Specimen Collection and Handling 
From January 1, 2003 through December 31, 2015, bone marrow and peripheral 
blood specimens with a clinical diagnosis of MDS were analyzed using conventional 
cytogenetic techniques including karyotyping and/or FISH.  These specimen types have 
the capability of spontaneous proliferation and the manner in which the samples are 
collected and handled upon arrival into the laboratory greatly influences the quality of 
analyses.    
Bone marrow aspirates and peripheral blood samples collected from 3992 
consecutive samples obtained from 2948 MDS cases and analyzed for cytogenetic and/or 
FISH studies performed at the Human Genetics Laboratory at the University of Nebraska 
Medical Center from 1990 to 2015 were examined.  Over the given time span, a variable 
number of specimens ranging from 1-13 were analyzed from each patient, thus explaining 
a total of 3992 consecutive specimens from 2948 MDS cases received in our laboratory.    
Sample Requirements for Blood and Bone Marrow:  Peripheral blood samples 
and bone marrow aspirate collection methods were essentially the same.  The specimens 
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were collected in sterile syringes or vacuum tubes containing preservation-free sodium 
heparin.  Typically, the first few milliliters of bone marrow is the optimum sample with the 
highest amount of cells.  In order to achieve the highest quality of results, 0.5 to 2.0mL of 
specimen was collected and transported at room temperature and processed for genetic 
studies in our laboratory.   
Conventional Cytogenetic Studies 
Traditional cytogenetic studies utilizes actively dividing cells; bone marrow and 
peripheral blood contain proliferating cells but when dividing cells are few in numbers, 
additives are used to stimulate mitosis.  Successful cytogenetic cultures had specific 
requirements for initiation, maintenance, and cell harvesting for optimum results.  
Prepared slides were stained using Giemsa banding (G-banding) techniques and analysis 
was performed using brightfield microscopes and fluorescence microscopes for FISH 
analyses in conjunction with a computerized imaging system for classical karyotyping 
(CytoVision® Image Analysis System, Leica Biosystems, Buffalo Grove, IL) (Figure 2). 
Specimen Culturing:  Peripheral blood and bone marrow specimens were grown and 
maintained in a liquid growth medium containing essential components for optimal cell 
growth that produced high quality banded karyotypes rapidly.  Chang Medium® BMC 
(Irvine Scientific, Irvine, CA) was used for human bone marrow and peripheral blood 
specimens for cytogenetic testing of hematological disorders.  Chang Medium® BMC 
consists of RPMI Medium 1640 with fetal bovine serum (FBS), essential for good cell 
growth; HEPES buffer to maintain the proper pH; L-glutamine, an essential amino acid, a 
component for maximum cell growth; gentamicin sulfate, used to inhibit microbial growth 
in the medium; and giant cell tumor extract a specially formulated growth factor for bone 
marrow cultures.   
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Chang Medium® BMC has been optimized to support efficient cell attachment and growth 
of bone marrow cells for cytogenetic analysis.  These cultures were grown in suspension 
using sterile 15mL screw cap centrifuge tubes in a slant rack placed within a 37oC 
incubator with 0.2 to 0.5mL of whole specimen added aseptically.  As described in Figure 
3, multiple cultures were initiated and incubated for 24 and 48-hour time periods.  In one 
culture, Colcemid® (Irvine Scientific, Irvine, CA) was added to block mitotic cells at 
metaphase.  For specimens collected and received on the same day in the laboratory, a 
direct culture (DIR) was set up which nearly eliminates cell culture time by treating the 
bone marrow aspirate with a solution containing 1XTrypsin-EDTA (Irvine Scientific, Irvine, 
CA), hypotonic salts, and 0.08ug/ml Colcemid® (THC).  The Trypsin-EDTA in this solution 
breaks up cell clusters and alters cell membranes, which facilitates better spreading of 
chromosomes during the slide preparation stage.  A hypotonic salt solution containing 
0.4% potassium chloride (KCL) was used to induce cell swelling and the simultaneous 
events of Trypsin-EDTA and KCL acted to "prime" the cells for the remaining steps of 
chromosome preparation.  The immediacy of the THC treatment, especially with regard to 
the action of Colcemid® in the hypotonic solution, gives a better representation of the 
mitotic index and proportion of various cell types in the marrow at the time of 
aspiration.  These cultures were incubated at 37oC in a slant rack for 20 minutes and were 
immediately harvested after the incubation time.  A direct overnight culture (DON) was 
initiated for specimens received in the laboratory at least one day after collection.  These 
cultures were incubated for 24 hours with Chang Medium® BMC and 10µl of Colcemid® 
(Dave, Wiggins et al. 2005, Dave, Hess et al. 1999, Higgins, Soe et al. 1993, Gersen, 





















Figure 3. Workflow of cytogenetic culture setup.  Culture setup for conventional 
cytogenetic studies based upon collection and received date of specimen.  (a) 
When specimens were collected and received on the same day, two cultures were 
inoculated with 0.5mL of specimen in Chang BMC media and incubated for 24 and 
48 hours before harvesting.  One culture was inoculated with 0.5mL of specimen 
in THC (1XTrypsin-EDTA, hypotonic salts, and 0.08ug/ml Colcemid®), incubated 
for 20 minutes, and harvested.  (b) When specimens were collected and received 
on different days, two cultures were inoculated with 0.5mL of specimen into Chang 
BMC media and incubated for 24 and 48 hours before harvesting.  One culture had 
0.5mL of specimen, Chang BMC media, and Colcemid® added, to block mitotic 
cells in metaphase, and was then incubated for 24 hours before harvesting. 
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Specimen Harvesting:  The harvesting of bone marrow and cancer blood samples was 
performed after the appropriate initial incubation period (20 minutes, 24 hours, or 48 
hours).  On the day of harvest, cultures were centrifuged for 6 minutes at 1500 rpm, the 
supernatant was aspirated off to 0.5-1.0 cm above the cell pellet, and 10mL of THC was 
added.  Cultures were incubated in a slant rack for 20 minutes at 37oC.  After the 
incubation time, suspension cultures were prefixed using 2mL of freshly prepared 3:1 
methyl alcohol glacial acetic acid (Mallinckrodt Pharmaceuticals, St. Louis, MO) fixative 
for a gentle initial lysing of red blood cells.  Specimen tubes were gently inverted to mix 
fixative and specimen culture and then spun at 1500 rpm for 6 minutes.  Supernatant of 
the fixed cell pellet was aspirated 0.5-1.0cm above the cell pellet and 6mL of fixative was 
added, inverted to mix, and spun for 6 minutes.  After aspirating the supernatant, 4mL of 
fixative was added, mixed with the culture, and spun for another 6 minutes.  This step was 
repeated until the supernatant was clear of lysed red blood cells.  After each fixation, the 
supernatant was removed closer to the cell pellet, approximately 0.5-1.0cm above to just 
above the cell pellet (Higgins, Soe et al. 1993, Howe, Umrigar et al. 2014).   
Slide Preparation:  After specimen culturing and harvesting, slide preparations were 
prepared from fixed cell pellets free of lysed red blood cells.  Fixed cells were dropped 
onto pre-cleaned cold, wet slides with a micropipette at a 45o angle.  To obtain optimum 
chromosome spreading and morphology, a temperature and humidity controlled 
environmental chamber was utilized during the slide preparation and drying process.  The 
Thermatron Drying Chamber CDS-5® (Venturedyne, Ltd., Holland, MI.) was set at 27oC 
and 47% relative humidity, which is ideal for metaphase spreads for bone marrows and 
peripheral bloods (Howe, Umrigar et al. 2014, Dave, Wiggins et al. 2005, Higgins, Soe et 
al. 1993).   
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Slide Staining:  To produce high-contrast permanent banding of chromosomes, G- 
banding techniques were utilized.  Unstained slides were aged by incubation in a 100oC 
hot oven for 25 minutes before staining reagents were applied to enhance the absorption 
of stain and to produce a more consistent banding pattern.  Slides with metaphase 
spreads were placed in 1X Trypsin-EDTA with Hanks Balanced Salt Solution (HBSS) 
(Irvine Scientific, Irvine, CA) for 6 seconds and then stained for approximately 50 seconds 
with Wright’s working stain, prepared by adding one-part Wright’s Stock Solution (Sigma-
Aldrich, St. Louis, Missouri) to two parts of pH 6.8 Gurr’s Buffer (BDH Laboratory, Poole, 
England).  After the appropriate time, slides were immediately rinsed with cold fresh water 
and air dried before analyses. 
Cytogenetic Analysis:  Giemsa-banded chromosomes were analyzed using bright-
field microscopes (Olympus BX models).  Image capture and karyotypic analysis was 
performed using CytoVision® Image Analysis System (Leica Biosystems, Buffalo Grove, 
IL, USA).  Karyotypes were described and documented according to the most recent 
International System for Human Cytogenetic Nomenclature (ISCN 2013) (Shaffer, 
McGowan-Jordan et al. 2013).  A minimum of 20 metaphases from at least two 
independently established cultures were examined, when possible, for each case.  The 
cells selected for analysis had a band-level resolution greater than or equal to 400 and a 
range of chromosome morphology for unbiased results.  A normal karyotype was defined 
as the lack of an identifiable abnormal clone in the metaphase cells analyzed.  An 
abnormal clone was defined, according to the ISCN guidelines, when three cells 
containing the same loss of chromosome and two cells showing the same gain of 
chromosome or structural abnormality was observed.  Independent clones, clonal 
evolution with one or more subclones, and complex karyotypes containing three or more 
aberrations were also reported according to ISCN guidelines.  Conventional chromosome 
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analysis is used at time of diagnosis as a prognostic tool and can be especially beneficial 
to track clonal evolution and progression of the disease (Dave, Wiggins et al. 2005, Valent, 
Horny 2009, Valent, Horny et al. 2007).  
Fluorescence in situ Hybridization (FISH) 
Fluorescence in situ hybridization techniques allow for the rapid and precise 
detection of specific nucleic acid sequences on interphase cells from fixed cells pellets 
following specimen initiation, maintenance, and harvesting as described previously.  This 
technique was applicable for the detection of aneuploidy, translocations, and the 
identification of small marker and derivative chromosomes.  This technique was a valuable 
addition to conventional cytogenetic analysis for diagnostic evaluation of hematologic 
disorders especially when metaphases were unavailable or suboptimal (Dave, Wiggins et 
al. 2005).  Figure 4 depicts the flow diagram describing the technical steps involved in the 
FISH process.  Fixed cells were dropped on clean slides specifically for FISH studies and 
probe mixtures were prepared and applied.  A series of steps including co-denaturation, 
hybridization, and counter staining were performed before FISH analysis was carried out.  
This technique utilized a defined panel of probes specific for characteristic chromosome 
aberrations observed in MDS patients (Pitchford, Hettinga et al. 2010).  The panel 
consisted of commercially available probes: LSI® EGR-1 (5q31)/D5S23, D5S721 (5p15.2) 
DNA Probe, the D7S486 (7q31)/CEP 7 (D7Z1) DNA Probe, and either the LSI® D20S108 
(20q12) DNA Probe (Abbott-Vysis) or the Cytocell Del(20q) (20q12 and 20q13.12) 
Deletion Probe (Cytocell, Cambridge, UK) cocktailed with the CEP 8 (D8Z1) DNA Probe 
(Abbott-Vysis, Abbott Park, IL) (Figure 5) (Dave, Wiggins et al. 2005, Dave, Hess et al. 
1999, Rigolin, Bigoni et al. 2001, Costa, Valera et al. 2010, Bernasconi, Cavigliano et al. 




Figure 4. Workflow of FISH studies.  Slides and probes were prepared 
before co-denaturation and hybridization occurred.  Slides were then 




Slide Preparation:  Fixed cells from cultured bone marrow were used to prepare slides 
specifically for FISH analyses.  Using the Thermatron Drying Chamber® provided a 
consistent environment for optimal results of 25oC temperature and 47% relative humidity 
during dropping.  On each slide, two areas were utilized for cell dropping.  Typically, 10µL 
of resuspended cells were placed on each hybridization area.  Once the slides were dry, 
the slides were examined under a phase contrast microscope to verify that an adequate 
number of interphase cells were present.  If inadequate numbers of cells were present, 
more cells were dropped on the specific hybridization area before proceeding with aging 
the cells in a hot oven at 100oC for two minutes (Dave, Hess et al. 1999).   
FISH Probe Preparation:  The preparation of probe and buffer mixtures from 
commercially purchased probes were performed after slide preparation.  Probes for the 
MDS specific abnormalities were mixed in a solution that contained 1µL of probe with 7µL 
of probe specific LSI or CEP hybridization buffer and 1µL of sterile, deionized water.  Only 
3µL of the probe mixture containing the specific probe, buffer, and water was applied to 
the hybridization area on the pre-warmed slide.  Each hybridization area was coverslipped 
with 12mm round coverslips and then sealed with rubber cement.   
Co-Denaturation and Hybridization:  Interphase cells and probes applied to the slide 
were co-denatured and hybridized using a HYBrite™ or a ThermoBrite™ instrument 
(Abbott-Vysis, Abbott Park, IL).  The co-denaturing and hybridization of both the target 
DNA and the specific probe set was performed at 78°C for 3 minutes and then 39°C 
overnight when using the HYBrite™ instrument.  When using the ThermoBrite™ instrument, 


































































































































































































































































Slide Washing:  Following hybridization, the rubber cement and round coverslips were 
removed and slides were washed with 0.4% sodium chloride and sodium citrate (SSC) 
(Sigma-Aldrich, St. Louis, MO) containing 0.3% Nonidet P-40 (NP-40) (Abbott-Vysis, 
Abbott Park, IL).  The wash solution was at a temperature of 72°C and was performed for 
2 minutes.  Slides were then placed in 2XSSC with 0.1% NP-40 for 1 minute at room 
temperature.  The slides were removed and air-dried before counter-staining.   
Counter Staining:  Slides containing interphase nuclei were counterstained with 10µL 
of 4,6-diamidino-2-phenylindole (DAPI II) in Antifade solution (Abbott-Vysis, Abbott Park, 
IL) proceeding co-denaturation, hybridization, and slide washing.  After the application of 
DAPI II, a 22x50mm coverglass was applied for slide protection and for microscopic 
analysis.     
FISH Analysis:  The prepared slides were analyzed using Olympus BX61 or Leica 
DM6000B fluorescence microscopes equipped with appropriate filters for individual colors: 
red, green, aqua, and DAPI as well as dual color red/green and DAPI/red/green filters.  
Hybridization signals, when available, were assessed in 50-200 interphase nuclei per 
probe.  A deletion or loss of DNA region was determined by the absence of probe signals 
specific for the region of interest with the presence of applied controls.  A gain was defined 
as the presence of greater than two individual probe signals specific for the region of 
interest.  Abnormal ranges were established for each specific probe and included 5-100% 
of total interphase cells observed for probes detecting -5, -7, +8, and concurrent deletions 
of 20q12-20q13.12; for deletions of 5q31 and 7q31 the abnormal range was 7-100%; and 
for a deletion of 20q12 the abnormal range was 10-100%.  Images were acquired, 
analyzed, and archived using the Leica Biosystems capture software, CytoVision® Image 
40 
 
Analysis System (Leica Microsystems, Buffalo Grove, IL)  (Dave, Wiggins et al. 2005, 
Dave, Hess et al. 1999, Rigolin, Bigoni et al. 2001). 
Microarray 
Microarray is a reliable and powerful molecular tool that can be used in conjunction 
with traditional cytogenetics to identify genomic alterations in MDS from bone marrow 
DNA.  This technique aids in providing an overview of DNA sequence copy number 
changes including losses, gains, and amplifications for the whole genome.  Unlike other 
molecular methods, microarray allows for a complete analysis of every chromosome in 
the genome using extracted DNA from whole bone marrow and peripheral blood (Bejar, 
Stevenson et al. 2011, Shih, Abdel-Wahab et al. 2012, Ismael, Shimada et al. 2012, Orazi, 
Germing 2008).  This method utilized the Affymetrix CytoScan® HD Array (Affymetrix, 
Santa Clara, CA) protocol that included a series of specific steps of DNA digestion, 
ligation, PCR, purification, fragmentation, labeling, hybridization, array washing, scanning, 
and analysis using the Affymetrix Chromosome Analysis Suite (ChAS) software.  For three 
cases, we utilized the Affymetrix OncoScan® FFPE Assay (Affymetrix, Santa Clara, CA) 
protocol to validate the use of whole bone marrow specimen on this platform.  This protocol 
contained a series of stages including annealing, gap filling, two rounds of PCR, digestion, 
hybridization followed by washing, staining, and scanning.   
DNA Extraction:  Genomic DNA was isolated from whole bone marrow and peripheral 
blood samples when sufficient specimen was available after conventional cytogenetic and 
FISH analyses.  DNA was extracted using the Qiagen QIAcube® automated robot and 
Qiagen spin column kits (Qiagen, Redwood City, CA).  The Qiagen QIAcube protocol 
utilized advanced technology to enable a completely automated, low-throughput sample 
preparation of DNA purification from a small amount of original specimen (400µl).  The 
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automated robot lysed the red blood cells of bone marrow and peripheral blood and bound 
the DNA to the Qiagen spin columns.  The bound DNA was washed and then eluted from 
the column leaving a total of 100µl of high quality DNA.   
DNA Quantification:  DNA samples that presented high quality, based upon 
spectrophotometry results, were used for microarray.  DNA quantification was determined 
using the Qubit™ 3.0 Fluorometer instrument (ThermoFisher Scientific, Waltham, MA).  
The Qubit® fluorometer uses commercially purchased standards and a small amount of 
purified DNA that enables a greater sensitivity and accuracy than UV absorbance 
measurements.  This analytical assay determined DNA quality of 40 to 400 µg/ml for 26 
of the 28 bone marrow and peripheral blood specimens collected for microarray studies.   
CytoScan® HD Array Assay Technique   
The Affymetrix CytoScan® HD Array offered high-density resolution of the entire 
genome, covering promotor and miRNA regions, for detection and reporting of 
abnormalities.  It provided maximum coverage for precise mapping of the whole genome 
for detecting copy number variations and copy neutral loss of heterozygosity (LOH) in 
addition to detecting novel submicroscopic deletions/duplications.  This assay included 
750,000 million SNPs with over 99% accuracy to detect chromosomal aberrations across 
the genome.  The CytoScan® Assay protocol was optimized for processing 8 to 24 
samples in parallel and followed eight stages of DNA digestion, ligation, PCR, PCR 
purification, PCR quantification, fragmentation, labeling, and hybridization.  After the 
arrays were hybridized, the chips were then washed and stained and scanned using the 
Affymetrix GeneChip® Scanner 3000 7G, controlled by the Affymetrix GeneChip® 
Command Center.  The exported array results were analyzed using the Affymetrix 
Chromosome Analysis Suite (ChAS) software. 
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CytoScan® HD Array Digestion:  Restriction enzyme digestion of the purified DNA 
sample utilized Nsp I enzyme.  A master mix of Affymetrix CytoScan® chilled nuclease-
free water, 10X Nsp I buffer, 100X BSA, and the Nsp I enzyme was prepared on ice (Figure 
6a).  Only 14.75µL of this master mix was aliquoted to 5.0µL of genomic DNA (50ng/µL) 
and 5.0µL of a negative control containing low EDTA TE buffer in a 96-well plate.  The 
plate was placed into a preheated GeneAmp™ PCR System 9700 thermocycler (Applied 
Biosystems, Waltham, MA) and the CytoScan® Digest program was set for approximately 
140 minutes before proceeding to stage two (Figure 6b).  
CytoScan® HD Array Ligation:  After digestion with Nsp I, adaptors were ligated 
using a master mix composed of Affymetrix CytoScan® 10X T4 DNA ligase buffer, 50µM 
Nsp I adaptor, and T4 DNA ligase (Figure 7a).  A fraction of the ligation mixture, 5.25µL, 
was added to the digested sample plate for a total reaction volume of 25µL.  The ligation 
plate was placed into a preheated thermocycler and the CytoScan® Ligate program ran 
for approximately three and a half hours (Figure 7b). 
CytoScan® HD Array Polymerase Chain Reaction (PCR):  Before PCR could 
proceed, the ligated samples were diluted with Affymetrix nuclease-free water.  The 25µL 
ligated DNA was diluted with 75µL of Affymetrix nuclease-free water to a final volume of 
100µL.  The PCR reaction utilized a Titanium™ DNA amplification kit (Clontech 
Laboratories, Takara Bio Company, Mountain View, CA) and water from Affymetrix 
CytoScan® reagents.  Only 10µL of the diluted samples were then transferred to four 
empty wells on a 96-well plate.  A PCR master mix was prepared with chilled Affymetrix 
nuclease-free water, 10X Titanium™ Taq PCR buffer, GC-melt reagent, dNTP mixture 
(2.5mM each), PCR primer (002), and 50X Titanium™ Taq DNA polymerase was added 

























Figure 6.  Restriction enzyme digestion CytoScan® protocol.  (a) The restriction 
enzyme digestion master mix utilized Affymetrix CytoScan® chilled nuclease-free 
water, 10X Nsp I buffer, 100X BSA, and the Nsp I enzyme.  (b) The digestion 
reaction was performed in a thermocycler for 140 minutes.  The process involves 















Figure 7.  Ligation CytoScan® protocol.  (a) The ligation master mix utilized 
Affymetrix CytoScan® 10X T4 DNA ligase buffer, 50µM Nsp I adaptor, and T4 DNA 
ligase. (b) The ligation reaction was performed in a thermocycler for approximately 





















   
                              
 
Figure 8. PCR CytoScan® protocol.  (a) The PCR master mix utilized chilled 
Affymetrix nuclease-free water, 10X Titanium™ Taq PCR buffer, GC-melt reagent, 
dNTP mixture (2.5mM each), PCR primer (002), and 50X Titanium™ Taq DNA 
polymerase. (b) The PCR reaction was performed in a thermocycler for 




The PCR plate was placed into a preheated thermocycler in the post-PCR area to avoid 
contamination.  A total of 90µL of the PCR master mix was added to each of the four 10µL 
ligated and diluted DNA samples.  The CytoScan® PCR program required approximately 
55 minutes for completion (Figure 8b).   
After the PCR reaction, 3µL of the product quality was determined by running it on 
a 2% TBE (Lonza Group, LTD, Switzerland) precast gel against 5µL of USB PCR marker 
50-2000bp (Affymetrix, Santa Clara, CA) ladder for 20 minutes at 5V/cm.  This gel 
contained ethidium bromide to visually observe the PCR product distribution.  The PCR 
product was confirmed as good quality and ready to proceed to PCR purification when the 
average product distribution was between 150 and 2000bp (Figure 9).   
CytoScan® HD Array PCR Purification:  Before the PCR product was purified, the 
aliquots of each sample were combined for a total of 397 µL (100µL from each well, minus 
3µL for the PCR gel).  After the samples were pooled, 720µL of Affymetrix CytoScan® 
purification beads were added to bind to the DNA in the PCR sample.  The DNA was 
separated using magnetic stands (MagnaRack, Life Technologies, Carlsbad, CA) that 
allowed the magnetic beads with bound DNA to be pulled aside.  The supernatant was 
removed and the pellet of DNA and beads was washed with 1mL of Affymetrix CytoScan® 
purification wash buffer.  The supernatant was then removed again with the use of 
magnetic stands.  DNA was eluted from the magnetic beads using 52µL of Affymetrix 
CytoScan® elution buffer and beads were pulled away from the DNA with the magnetic 






















Figure 9. Verification of the PCR product.  The product was of good quality when 
the average product distribution was between 150 and 2000bp on a 2% TBE gel. 
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CytoScan® HD Array PCR Quantification:  After the PCR product was purified, the 
quantification of the DNA was determined using a NanoDrop® Spectrophotometer ND-
1000 (NanoDrop Technologies, Inc., Wilmington, DE).  The DNA sample was first diluted 
using 18µL of Affymetrix nuclease-free water and 2µL of product.  The NanoDrop® was 
blanked with water and 2µL of the diluted sample was measured at OD260/OD280.  The 
DNA yield was within the acceptable range of 250ng/µL and above in order for 
fragmentation to be initiated. 
CytoScan® HD Array Fragmentation:  The fragmentation stage has critical 
temperature sensitivities and in order to ensure uniform, reproducible fragmentation this 
step was performed rapidly on ice and in a plate centrifuge at 4oC.  The fragmentation 
master mix was made using Affymetrix CytoScan® reagents with a concentration of 
2.25U/µL.  The master mix included chilled Affymetrix nuclease-free water, 10X 
fragmentation buffer, and fragmentation reagent (Figure 10a).  An amount of 10µL of the 
fragmentation master mix was added directly to the purified PCR products in a 96-well 
plate on ice.  The plate was transferred to a preheated thermocycler and the CytoScan® 
fragment program was performed for approximately 50 minutes (Figure 10b).  
Once the fragmentation program was completed, the sample was removed and 
the products were checked on a 4% TBE (Lonza Group, LTD, Switzerland) precast gel at 
5V/cm for 19 minutes.  The finished product was diluted using 4µL of the finished 
fragmented sample with 28µL of water and a further dilution of 8µL of the original dilution 
added to 12µL of water.  The final diluted fragmentation sample was loaded onto the gel 
against the TrackIt™ 25bp DNA ladder (Life Technologies, Carlsbad, CA) to determine the 
distribution of the product.  The majority of fragmented PCR products were between 25 to 




















Figure 10.  Fragmentation CytoScan® protocol.  (a) The fragmentation master 
mix utilized chilled Affymetrix CytoScan® reagents with a concentration of 2.25U/µL 
and included Affymetrix nuclease-free water, 10X fragmentation buffer, and 
fragmentation reagent.  (b) The fragmentation reaction was performed in a 




















Figure 11. Verification of the fragmentation product.  The product was of good 
quality when the majority of the product distribution was between 25 and 125bp on 
a 4% TBE gel. 
51 
 
CytoScan® HD Array Labeling:  The fragmented PCR product was labeled using 
terminal deoxynucleotidyl transferase (TdT) enzyme.  The master mix solution was 
composed of Affymetrix CytoScan®5X TdT buffer, 30mM DNA labeling reagent, and TdT 
enzyme (Figure 12).  A portion (19.5 µL) of the labeling mix was added to the remaining 
51.0µL of fragmented DNA; 4.0µL was used for the fragmentation gel analysis.  The plate 
was transferred to a preheated thermocycler and the CytoScan® label program was 
performed for approximately 4 hours and 15 minutes (Figure 12b).   
CytoScan® HD Array Hybridization:  Target hybridization was performed using the 
Hybridization Oven 645® at a temperature of 50oC at a rotation speed of 60rpm.  Arrays 
for each patient were recorded and entered into the Affymetrix GeneChip® Command 
Center® 3.2 and then left at room temperature until they were loaded.  A hybridization 
master mix was made using the Affymetrix CytoScan® Hyb buffer part 1, Hyb buffer part 
2, Hyb buffer part 3, Hyb buffer part 4, and oligo control reagent 0100 (Figure 13a) and 
190µL of the mix was added to the labeled samples.  The plate was placed into the 
thermocycler and the CytoScan® Hyb program ran for about 10 minutes (Figure 13b).  
When the thermocycler reached 49oC, the samples were injected into the septa of the 
array and covered with ½” Microtube Tough-Spots (Diversified Biotech, Boston, MA).  The 
arrays were placed into an oven tray evenly spaced and allowed to rotate at the 
appropriate temperature and speed for 16 to 18 hours.   
OncoScan® FFPE Assay Technique 
The OncoScan® Assay utilized the Molecular Inversion Probe (MIP) assay 
technology for genome wide copy number and LOH profiles.  This test was developed to 
perform well with highly degraded DNA.  This protocol is typically reserved for fixed 




















Figure 12. Labeling CytoScan® protocol.  (a) The labeling master mix utilized 
Affymetrix CytoScan®5X TdT buffer, 30mM DNA labeling reagent, and TdT 
enzyme.  (b) The labeling reaction was performed in a thermocycler for 





















Figure 13. Hybridization CytoScan® protocol.  (a) The hybridization master mix 
utilized Affymetrix CytoScan® Hyb buffer part 1, Hyb buffer part 2, Hyb buffer part 
3, Hyb buffer part 4, and oligo control reagent 0100.  (b) The labeling reaction was 
performed in a thermocycler for approximately 10 minutes. 
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100 ng DNA of starting material, which makes it the ideal assay for clinical cancer 
research.  This laboratory validated the use of this assay on DNA extracted from whole 
bone marrow specimen for future research use.  The OncoScan® Assay protocol was 
optimized for processing 6 to 24 samples in parallel and followed five stages of annealing, 
gap fill through first PCR, second PCR, HaeIII digestion, and hybridization.  After the 
arrays were hybridized, the chips were then washed and stained and scanned using the 
Affymetrix GeneChip® Scanner 3000 7G, controlled by the Affymetrix GeneChip® 
Command Center.  The exported array results were analyzed using the Affymetrix 
Chromosome Analysis Suite (ChAS) software. 
OncoScan® Annealing:  Genomic DNA was normalized to 12ng/µL using 1X TE (pH 
8.0) with reduced EDTA (0.1Mm EDTA) before annealing of probe mixes occurred.  A 
master mix of Affymetrix OncoScan® buffer A, copy number probe mix 1.0, and somatic 
mutation probe mix 1.0 was prepared on ice (Figure 14a).  Only 3.4µL of this master mix 
was aliquoted to 6.6µL of DNA leaving a total volume of 10µL.  The OncoScan® positive 
and negative control included in the reagent kit was also added to the 96-well plate.  The 
plate was placed into a GeneAmp™ PCR System 9700 thermocycler (Applied 
Biosystems, Waltham, MA) and the OncoScan® Anneal program ran overnight, for 
approximately 16-18 hours (Figure 14b).   
OncoScan® Gap Fill through first PCR:  After the overnight anneal program, the 
plate was removed and the OncoScan® Gap Fill program was started.  Once the 
temperature reached 58oC, the program was paused.  The gap fill master mix was created 
and contained Affymetrix OncoScan® nuclease-free water, buffer A, SAP recombinant 





















Figure 14. Anneal OncoScan® protocol.  (a) The anneal master mix utilized 
Affymetrix OncoScan® buffer A, copy number probe mix 1.0, and somatic mutation 






















Figure 15.  Gap fill OncoScan® protocol.  a) The gap fill master mix utilized 
OncoScan® nuclease-free water, buffer A, SAP recombinant, and gap fill enzyme.  
b) The dNTP master mixes utilized nuclease-free water and the specific dNTP 
mixes (AT and GC).  c) The cleavage master mix utilized cleavage buffer and 
enzyme.  d) The gap fill reaction was performed in a thermocycler for approximately 
90 minutes.   
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added to each reaction for a final volume of 24.0µL and left on ice while the first PCR plate 
was created. 
The first PCR step required that the AT mix and GC mix be created independently 
in order to avoid contamination.  Each mix contained Affymetrix OncoScan® nuclease-
free water and the specific dNTPs (A/T or GC) (Figure 15b).  A fresh 96-well plate, labelled 
first PCR, was used and designated rows for AT and GC were labeled.  From the anneal 
plate, 10µL of the gap fill reactions were aliquoted into the wells of the two designated 
rows on the first PCR plate.  The plate was loaded on the thermocycler and the Gap Fill 
program was resumed at 58oC for 11 minutes.  After this time, the program was paused 
and the first PCR plate removed to add 4µL of the A/T mix to each of the wells in the A/T 
designated row.  The same amount of G/C mix was added to each of the wells in the G/C 
designated row on the first PCR plate.  The plate was loaded back onto the thermocycler 
and the program was resumed for another 11 minutes.  The program was paused before 
the cycler ramped down to 37oC.  The first PCR plate was removed and 3µL of Affymetrix 
OncoScan® Exo Mix reagent was added to each reaction for a final volume of 17µL.  The 
plate was loaded back onto the cycler and the program was resumed.  During the last 5 
minutes of the program at 95oC, the cleavage master mix was created using Affymetrix 
OncoScan® cleavage buffer and cleavage enzyme (Figure 15c).  The program was 
paused when the thermocycler reached the start of the 37oC step and 25µL of the 
cleavage mix was added to each reaction.  The thermocycler program was resumed and 
finished after 30 minutes (Figure 15d).   
The first PCR master mix was created during the last 5 minutes of the Gap Fill 
program and consisted of Affymetrix OncoScan® PCR mix and Taq polymerase (Figure 

















Figure 16.  First PCR OncoScan® protocol.  a) The first PCR master mix utilized 
OncoScan® PCR mix and Taq polymerase.  b) The first PCR reaction was 




PCR master mix was added to each reaction.  The OncoScan® First PCR program on the 
thermocycler was started and once the cycler reached 60oC the plate was loaded and ran 
for approximately 20 minutes (Figure 16b).   
OncoScan® Second PCR:  The second PCR stage occurred in the post-PCR lab.  A 
fresh 96-well plate was labeled as the second PCR plate and designated AT and GC rows 
were marked.  The second PCR master mix utilized OncoScan® PCR mix and Taq 
polymerase and 25µL of this mix was aliquoted to each of the designated wells (Figure 
17a).  From the first PCR plate, 2µL were removed and added to the corresponding wells 
on the second PCR plate.  This plate was loaded onto the thermocycler and the 
OncoScan® Second PCR program ran for approximately 20 minutes (Figure 17b).   
A quality control gel was used to check the first PCR product.  From the first PCR 
plate, 8µL from each well were loaded onto a 3% precast agarose gel with a 50bp ladder 
(New England Biolabs, Ipswich, Massachusetts).  The gel ran for 15 minutes at 150V/cm 
and the PCR products were determined of good quality when they were approximately at 
120bp (Figure 18).   
OncoScan® Digestion:  Smaller DNA fragments were generated to improve the 
sample hybridization onto the array during the HaeIII digestions.  A fresh 96-well plate 
labeled HaeIII was used and the appropriate AT and GC rows were designated.  The 
digestion master mix utilized OncoScan® buffer B, HaeIII enzyme, and exo enzyme 
(Figure 19a).  From the master mix, 20µL was aliquoted to the appropriate wells of the 
HaeIII plate with 10µL of the second PCR amplified reaction.  The plate was loaded on 





















Figure 17.  Second PCR OncoScan® protocol.  a) The second PCR master mix 
utilized OncoScan® PCR mix and Taq polymerase.  b) The second PCR reaction 





















Figure 18.  Verification of the first PCR product.  The product was of good quality 













Figure 19.  HaeIII Digestion OncoScan® protocol.  a) The HaeIII digestion 
master mix utilized OncoScan® buffer B, HaeIII enzyme, and exo enzyme.  b) The 




The quality of the HaeIII digestion was determined by running a 3% precast 
agarose gel.  The thermocycler was paused after the 88 minutes at 37oC and 4µL of the 
digest reaction was removed from each well.  The thermocycler program was resumed 
and the gel was loaded with 4µL of the reaction and 3.5µL of a 50bp ladder and ran for 15 
minutes at 150V/cm.  The gel was examined and determined of good quality when doublet 
bands around 40-70bp were observed (Figure 20).      
OncoScan® Hybridization:  Target hybridization was performed using the 
Hybridization Oven 645® at a temperature of 49oC at a rotation speed of 60rpm.  Two 
arrays for each patient (AT and GC) were recorded and entered into the Affymetrix 
GeneChip® Command Center® 3.2 and then left at room temperature until they were 
loaded.  A hybridization master mix was made using the Affymetrix OncoScan® nuclease-
free water and hybridization mix (Figure 21a).  To a new 96-well plate labeled Hyb, 190µL 
of the mix was added to the appropriate wells for each reaction.  From the HaeIII plate, 
22µL of the digestion reaction was aliquoted to the hybridization plate.  The plate was 
loaded into the thermocycler and the OncoScan® Hybridization program ran for about 15 
minutes (Figure 21b).  When the thermocycler reached 49oC, the samples were injected 
into the septa of the array and covered with ½” Microtube Tough-Spots (Diversified 
Biotech, Boston, MA).  The arrays were placed into an oven tray evenly spaced and 
allowed to rotate at the appropriate temperature and speed for 16 to 18 hours.   
Array Washing and Staining:  The hybridized arrays (CytoScan® and OncoScan®) 
were removed from the hybridization oven between 16 and 18 hours from the time of 
incubation.  Tough-Spots were removed from the septa on the arrays before being 
inserted into the array-designated modules of the GeneChip® Fluidics Station 450.  The 




















Figure 20.  Verification of the HaeIII digestion product.  The product was of good 























Figure 21.  Hybridization OncoScan® protocol.  a) The hybridization master mix 
utilized OncoScan® nuclease-free water and hybridization mix.  b) The hybridization 




proceeding with the washing and staining stage.  In the position labelled 1, 500µL of stain 
buffer 1 was placed into a 1.5mL microfuge tube.  Position 2 contained a 1.5mL microfuge 
tube containing 500µL of stain Buffer 2 and 800µL of array holding buffer was aliquoted 
into a 1.5mL microfuge tube and placed into position 3.  The fluidics protocol was started 
using the Affymetrix GeneChip® Command Console and ran for approximately 1 hour.   
Array Scanning:  When the wash and stain procedure was finished, arrays were 
removed and checked for bubbles or air pockets and returned to the fluidics station if 
present.  Once air was removed, the septa on the arrays were closed using ½” Microtube 
Tough-Spots and placed into the GeneChip® Scanner 3000 7G and scanned.   
Microarray Analysis:  Analysis was performed with the Affymetrix Chromosome 
Analysis Suite (ChAS) software.  The classification of the microarray results was based 
on the reference ranges established in validation for the array test type performed by this 
laboratory.  The detection rate for mosaicism was determined above 20-25% by validation.  
The size threshold for gains was set at 5Kb and losses set at 10Kb.  The threshold for 
LOH was set at 3120Kb.  Analysis of each chromosome was performed using the 
software, aberrations were flagged by the system, and the size of the anomaly was 
determined.  Further investigation of each chromosome was performed by a manual 
examination of the smooth signal for peaks and dips to determine gains or losses not 
flagged by the ChAS software (Figure 22).  When these aberrations were observed, the 
location and size was manually determined.  A benign classification was determined when 
no genes were seen, an overlap with the Database of Genomic Variants (DGV) or NCBI 
Database for Genomic Structural Variants (dbVAR) was present, or when an overlap with 
a recurring del/dup region or CNV based upon the Fullerton and Cooper overlap maps 
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backbone, greater than 5Kb intragenic involving exons or a single gene and at the time of 
the analysis there was not sufficient evidence available for a determination of clinical 
significance.  A designation of pathogenic was given when the abnormality was 
cytogenetically visible, when overlapped with a known cancer gene was observed, or 




































From January 1, 1990 to December 31, 2015, bone marrow aspirates and 
peripheral blood samples were collected for conventional cytogenetic and/or FISH 
analysis on cases with a clinical diagnosis of MDS.  A total of 3992 specimens from 2948 
individual cases were studied.  The 2948 cases included 1666 males and 1282 females 
with an age range of 0 to 99 years with the highest prevalence in the 7th and 8th decade of 
life (Figure 23).  This data coincides with the current knowledge that MDS is frequently 
observed in the elderly population.  Of the 3992 total number of specimens received into 
the laboratory, 306 specimens (7.6%) were from pediatric or young adult cases, or those 
between the ages of 0 and 29.  Further delineation of the younger population shows 205 
(5.1%) specimens were from pediatric only patients aged 0 to 18 years and 101 (2.5%) 
specimens were from young adults or those between 19 to 29 years of age (Figure 24). 
Pediatric Patient Demographics 
From the given time span, our laboratory analyzed 306 bone marrow or peripheral 
blood samples with a clinical diagnosis of MDS from pediatric and young adult cases, or 
those between the ages of 0 and 29 years.  These samples were from 177 cases.  Over 
the given time span, a variable number of specimens ranging from 1 to 12 were analyzed 
from each patient, thus explaining a total of 306 consecutive specimens.  The younger 
population of MDS cases consisted of 95 males and 82 females with the most prevalent 
age of occurrence in the first year of life (Figure 25).  Of these cases, 205 specimens were 
collected from 119 pediatric cases rangin16g from 0-18 years of age.  The specimens 
from pediatric cases were from 65 males and 54 females.  The young adult population, 
19-29 years of age, consisted of 101 specimens from 58 cases with the most prevalent 




















Figure 23.  Demographic distribution of MDS.  The 2948 bone marrow or 
peripheral blood cases with a clinical diagnosis of MDS over the time span of 1990-
2015 included 1666 males and 1282 females.  The age ranged from 0 to 99 years 























Figure 24.  Percentage of MDS specimens per age group.  From the 3992 total 
number of specimens received in our laboratory over the given time span of 1990-
2015, 205 (5.1%) specimens were from the pediatric population aged 0 to 18 years 
and 101 (2.5%) specimens were from young adult samples (19 to 29 years).  The 
majority of the specimens, 3686 (92%), were from the adult population, aged 30 




















Figure 25.  Demographic distribution of pediatric and young adult MDS.  From 
1990-2015, this laboratory analyzed 306 bone marrow or peripheral blood samples 
with a clinical diagnosis of MDS from 177 pediatric and young adult cases.  The 
pediatric cases consisted of 95 males and 82 females with the most prevalent ages 




Conventional Cytogenetic and FISH Analyses  
The cytogenetic and FISH data comparison was performed on the total number of 
specimens received into the laboratory.  Over the given time span of 1990 to 2015, a total 
of 3992 MDS specimens from 2948 individual cases were studied in our laboratory.  
Cytogenetic and FISH analyses were performed on each specimen in order to detect 
chromosome aberrations and to accurately determine disease clonality and monitor 
disease progression.     
Of the 3992 MDS specimens, 2353 (58.9%; 2353 / 3992) presented a normal 
cytogenetic karyotype and FISH results.  A total of 1639 (41.1%; 1639 / 3992) samples 
presented abnormal findings by conventional cytogenetics and/or FISH analyses.  One of 
the hallmark chromosome abnormalities commonly observed in MDS patients [-5/del(5q), 
-7/del(7q), +8, and del(20q)] (Figure 26a-d) was observed in 1155 of the abnormal studies 
(70.5%; 1155 / 1639) (Figure 27).  Abnormalities not typical of MDS identified by 
cytogenetics and confirmatory or concurrent FISH included chimerism of donor and host 
cells in post-transplant patients, a variety of deletions and rearrangements, and random 
gains and losses of chromosomes not typically associated with MDS.  Each one of these 
were in frequencies of less than 1.5%.  In the adult population, an MDS-related 
abnormality was detected by cytogenetic karyotyping and/or FISH in 1099 specimens as 
either the sole anomaly or as part of a complex karyotype with more than one anomaly 
present, MDS-related or not.  The frequencies of each hallmark abnormality observed was 
determined for this population.  The most frequent MDS-related abnormality observed was 
-5/del(5q), seen in 519 adult samples.  The -7/del(7q) abnormality was the next most 

























   
   
  
   
 
   
 
 
   
   


















































































































Cytogenetic/FISH Findings of 2353 Specimens from Adult MDS  
(≥30 Years of Age) Cases 
 
 
Figure 27.  Cytogenetic/FISH Findings of 2353 specimens from adult MDS 
(≥30 years of age) cases.  From the given time span, 2353 (58.9%) bone marrow 
or peripheral blood samples with a clinical diagnosis of MDS contained a normal 
cytogenetic karyotype and normal FISH results.  An abnormal cytogenetic 
karyotype and/or FISH analyses was observed in 1639 (41.1%).  From these 
samples, 1155 (70.5%) contained one of the four hallmark MDS chromosomal 
abnormalities of -5/del(5q), -7/del(7q), +8, or del(20q).  The remaining 484 (29.5%) 
of the cases contained an abnormality not typical of MDS.   
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The least frequent MDS-related abnormality observed in the adult population, or those 
over the age of 30, was del(20q) in 260 specimens (Table I).     
Conventional Cytogenetic and FISH Analyses of Pediatric Population 
MDS is a rare disease among pediatric and young adults, between the age of 0 
and 29 years.  A fraction of the total number of MDS specimens analyzed over the given 
time span included this population, 7.6% (306 / 3992).  Among the 306 specimens from 
pediatric and young adult cases, 230 (75.2%; 230 / 306) presented normal results by 
conventional cytogenetics and FISH analyses.  Among the 76 abnormal specimens 
(24.8%; 76 / 306), one or more of the hallmark MDS-related cytogenetic abnormalities was 
observed in 56 samples (73.7%; 56 / 76) (Figure 28).  The most frequent chromosomal 
abnormality observed was -7/del(7q) in 28 samples.  Trisomy 8 was observed in 13 
samples and del(20q) in 10 samples.  Unlike the adult population, among the pediatric 
and young adult specimens the -5/del(5q) was the least frequent abnormality observed in 
8 specimens (Table II).   
Further delineation between the pediatric (0-18) and young adult (19-29) 
population presented similar frequencies of MDS-related chromosome abnormalities thus 
providing the justification for expanding the pediatric analysis to include the young adults.  
Of the 205 pediatric only (0-18 years) specimens, 150 presented normal karyotypes and 
negative FISH results (73.2%; 150 / 205).  Of the 55 abnormal specimens (26.8%; 55 / 
205), 43 (78.2%; 43 / 55) samples contained one of the hallmark MDS-related cytogenetic 
abnormalities (Figure 29). Among the 101 young adult (19-29) specimens, 80 (79.2%; 80 
/ 101) presented normal cytogenetic and FISH findings.  Of the 21 (20.8%) abnormal 





















Table I. Characterization of the MDS-related chromosomal 
abnormalities detected by cytogenetic and FISH analyses in adult MDS.  
The most frequent MDS-related abnormality observed was -5/del(5q), seen in 519 
adult specimens followed by -7/del(7q) in 423 samples; and +8 in 282 samples.  
The least frequent MDS-related abnormality observed in the adult population was 













Figure 28.  Cytogenetic/FISH findings of pediatric and young adult MDS.  From 
the given time span of 1990-2015, 230 pediatric and young adult specimens 
(75.2%) presented normal results by conventional cytogenetics and FISH analyses.  
Among the 76 (24.8%) abnormal samples, 56 (73.7%) contained one or more of 
the hallmark MDS-related cytogenetic abnormalities and an abnormality not typical 
of MDS was noted in 20 (26.3%) samples.   























Table II.  Characterization of the MDS-related chromosomal 
abnormalities detected by cytogenetic and FISH analyses in the 
pediatric/young adult population. In the pediatric and young adult population, 
0-29 years, the most frequent chromosomal abnormality observed was -7/del(7q) 
in 28 specimens.  Trisomy 8 was observed in 13 samples and del(20q) in 10 
samples.  The least frequent abnormality in the pediatric and young adult 




















Cytogenetic/FISH Findings of Pediatric MDS  
  
             
Figure 29.  Cytogenetic/FISH findings of pediatric MDS.  From 1990-2015, 205 
total pediatric only (0-18 years) specimens were analyzed and 150 (73.2%) of them 
had a normal cytogenetic karyotype and FISH analyses.  Out of the 55 specimens 
(26.8%) with abnormal findings, 43 specimens (78.2%) contained one of the 
hallmark MDS aberrations.   
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abnormalities (Figure 30).  The most frequent abnormality of -7/del(7q) was observed in 
17 pediatric samples.  Trisomy 8 and del(20q) was observed in 10 samples; and -5/del(5q) 
was only observed in five samples among the 0-18 age group.  Among the young adult 
population, -7/del(7q) was observed in 9 specimens and +8 and del(20q) was seen in 3 
samples each.  The least frequently observed abnormality of -5/del(5q) was observed in 
3 specimens from the 19-29 age group (Table III).   
The 20 specimens with a chromosome abnormality not typical of MDS had a range 
of abnormalities.  The most common other abnormality detected by cytogenetics and FISH 
in the younger population was constitutional trisomy 21, observed in 8 samples (14.2%; 8 
/ 56).   Other abnormalities included the following; chimerism of donor and host cells in 
post-transplant patients; loss of Y and 13; deletion of 6q; rearrangements of 11q, 14q, 
18q, 19q; and gain of chromosome 19.  Each one of these were in frequencies of 1.0% or 
less. 
Microarray Samples 
Between January 1, 2012 to January 1, 2015, bone marrow or peripheral blood 
from pediatric or young adult MDS cases was saved when the original specimen was in 
excess after all cytogenetic and FISH studies were performed.  These samples were used 
for extraction of DNA for high-resolution array studies.  These cases were chosen based 
solely on their volume of original specimen and not for their cytogenetic or FISH findings.  
From the 93 pediatric or young adult MDS cases received in the Human Genetics 
Laboratory between 2012-2015, only 28 specimens contained excess whole bone marrow 
or blood after cytogenetic and FISH studies and were from cases with a variety of ages 




















Cytogenetic/FISH Findings of Young Adult MDS  
 
            
Figure 30.  Cytogenetic/FISH findings of young adult (19-29 years) MDS.  Over 
the given time span, 101 total specimens from young adult (19-29 years) 
specimens were analyzed and 80 (79.2%) presented normal cytogenetic and FISH 
findings.  Of the 21 (20.8%) abnormal specimens, 13 (61.9%; 13/21) contained one 





















Table III.  Comparison of MDS-related abnormalities observed in the 
pediatric and young adult MDS populations.  The observance of the 
hallmark abnormality of -7/del(7q) was comparable between the two groups with 
this being the most observed aberration.  The next most frequent abnormalities 





















Table IV.  List of pediatric and young adult MDS specimens 
for microarray studies after karyotyping and FISH 
analyses.  The table lists the case ID, age of patient at time of 
intake, cytogenetic karyotyping and FISH results for the 28 cases 
sent for microarray testing. 
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Only five of these cases were from the young adult population, or those between 
the ages of 19 and 29.  From the total cases, 21 presented normal karyotypes (Figure 31) 
and FISH results (Figure 32).  Our justification for using cases with normal cytogenetic 
and FISH findings is due to the possible presence of cryptic abnormalities that can only 
be detected by high-resolution techniques.  The six cases with abnormal cytogenetic or 
FISH results contained the following abnormalities;  
45,XX,-7; 45,XY,-7; 45,XY,-7; 46,XX,inv(11)(q13q23); 46,XY,del(20)(q12q13); and 
46,XY,del(20)(q12q13).       
Microarray Results 
Out of the 28 pediatric and young adult MDS specimens available, microarray 
analysis was performed on 26 cases.  Two cases were not utilized on array due to 
insufficient DNA yields.  From the 26 cases, 15 (58%; 15 / 26) were found to contain 
genetic alterations that were determined to be pathogenic or likely pathogenic (Figure 33).  
From this study, 33 gene aberrations detected were determined as pathogenic or likely 
pathogenic and were MDS-associated genes and/or genes involved in hematopoiesis, cell 
cycle proliferation/regulation, apoptosis, known tumor suppressor genes, or other disease-
associated genes (Table V).  Of particular importance, eight of these genetic aberrations 
were detected in more than one case.  Further analysis found that out of the five young 
adult specimens, three specimens had a detectable pathogenic aberration and some of 
these pathogenic changes were observed in the pediatric population, 0-18 age group.  
These results further justify our non-restrictive use of young adult specimens included into 


































































































































































































































































































Figure 33.  Microarray findings of pediatric and young adult MDS cases.  From 
the 26 total pediatric and young adult MDS cases, microarray determined that over 
58% (15 cases) contained a genetic alteration that was determined to be 
pathogenic or likely pathogenic.    






















Table V.  Characterization of genetic aberrations detected by 
microarray.  A total of 33 genes were altered among the pediatric and young adult 
MDS cases by microarray.  The top eight gene aberrations listed in the table were 
detected in more than one case.  This table lists the gene name, the chromosome 







Case 1 was a bone marrow aspirate from a 2-year-old female with a normal 
cytogenetic karyotype and negative for the MDS FISH panel.  High-resolution array 
studies using the ChAS software detected 20 aberrations in the form of gains, losses, or 
regions of LOH.    Based upon the call parameters previously discussed, 19 of the 20 
aberrations were classified as benign.  A 532kbp pathogenic gain was observed by 
manual examination of the smooth signal on chromosome 16q24.3 located at chr16: 
88,722,097 - 89,254,728, which overlaps with the CBFA2T3 gene (16: 88,874,854 - 
88,977,198) (Figure 34).  This gene is associated with AML and therapy-related myeloid 
malignancies as determined from the Online Mendelian Inheritance in Men® (OMIM) 
online catalogue and the National Center for Biotechnology Information (NCBI).  
Case 2 
Case 2 was a bone marrow aspirate from a 16-year-old male that presented a 
normal karyotype and was negative for the MDS FISH panel.  There were 32 benign 
aberrations based on the classification criteria.   
Case 3 
A bone marrow aspirate from a 10-year-old male presented a normal cytogenetic 
karyotype and negative FISH analyses.  This case detected 32 aberrations in the form of 















































































































































In Case 4, high-resolution array studies using the ChAS software detected 41 
aberrations in the form of gains, losses, or regions of LOH; 39 of the 41 aberrations were 
classified as benign.  Two aberrations were determined to overlap with pathogenic genes.  
A 3,558kbp mosaic gain was detected by the ChAS software on chromosome 1p36.33 
located at chr1: 849,466 - 4,408,084 which overlaps with the PRDM16 gene (1: 3,068,226 
- 3,438,620), an MDS-related gene (Figure 35a).  Further examination of the smooth signal 
in ChAS detected a 247kbp loss on chromosome 6p21.2 located at chr6: 36,988,591 - 
37,236,435.  This aberration overlaps with the PIM1 gene (6: 37,170,145 - 37,175,427), a 
known oncogene involved in hematopoiesis (Figure 35b). 
Case 5 
In case 5, FISH analyses were positive for a deletion of 20(q12q13) in 13% of the 
interphase cells (Figure 36).  This deletion was not detected by microarray studies due to 
the low-level mosaicism.  However, microarray detected a 98kbp likely pathogenic deletion 
on chromosome 2 within the p23.3 region.  The location of this deletion ranged from 
29,607,409 through 29,706,398, which overlaps with a small portion of the ALK gene (2: 
29,192,773 - 29,921,610), a known oncogene involved in various cancers as determined 
by OMIM and NCBI (Figure 37).     
Case 6 
 This bone marrow aspirate was from a 3-month old female with a normal 
karyotype and negative for the MDS FISH panel.  Twenty-six aberrations were classified 
as benign in case 6 by microarray studies.  Two benign aberrations originally predicted to 






















Figure 35.  Microarray results for Case 4.  Two pathogenic 
aberrations were detected and were determined to overlap 
with pathogenic genes. a) A 3,558kbp mosaic gain was 
detected on chromosome 1p36.33 which overlaps with the 
PRDM16 gene, an MDS-related gene.  b) A 247kbp loss was 
observed on chromosome 6p21.2 which overlaps the PIM1 





















Figure 36.  FISH results for Case 5.  The FISH MDS panel detected a deletion of 
20q12 and 20q13 with normal karyotypes in case 5.  This image shows only one 
copy of each of the 20q probes.   






















Figure 37.  Microarray results for Case 5.  One likely pathogenic aberration was 
detected and determined to overlap with a pathogenic gene. A 98kbp deletion was 




after further detailed examination following initial review using the ChAS software.  
Examination and comparisons of the aberration and gene locations determined that these 
aberrations did not result in the loss of the CASP9 (1p36.13) and FGFR1OP (6q27) genes 
as previously predicted (Figure 38a-b).     
Case 7 
Case 7 was a bone marrow aspirate from an 11-year-old female that presented an 
abnormal cytogenetic karyotype of 46,XX,inv(11)(q13q23) in 17 cells and was abnormal 
for the MLL (11q23) Breakapart FISH probe in 67% of interphase cells (Figure 39).   The 
remaining MDS FISH panel was negative.  The disruption of this gene cannot be detected 
by microarray studies.  Balanced genomic alterations are not determined by microarray 
but three additional changes were determined to overlap pathogenic genes.  A 774kbp 
gain was observed on chromosome 1p36.33 located at chr1: 2,910,012 - 3,684,184 that 
overlaps with the MDS-related PRDM16 gene (1: 3,068,226 - 3,438,620).  Manual 
examination detected a 249kbp gain on chromosome 11p11.2 located at chr11: 
44,100,800 - 44,350,320 that overlaps the tumor suppressor EXT2 gene (11: 44,095,548 
- 44,245,429).  Finally, a 674kbp loss on chromosome 22q12.1 located at chr22: 
28,680,003 - 29,354,770 that overlaps the CHEK2 gene (22: 28,687,742 - 28,741,904) 
was observed.  The CHEK2 gene has been shown to play a role in cell proliferation and 
tumor progression (Figure 40a-c).   
Case 8 
A normal karyotype was presented in case 8 and FISH studies were cancelled by 
the requesting physician.  High-resolution array studies using the ChAS software detected 




















Figure 38.  Microarray results for Case 6.  ChAS originally predicted the overlap 
of a) 349kbp loss on chromosome 1p36.13, overlapping the apoptotic gene CASP9 
and b) 525kbp loss on chromosome 6q27, overlapping the MPD-related gene 
FGFR1OP.  Further examination determined the losses as benign.  The actual 
locations were over 144kbp and 148kbp downstream of the gene, respectively.  
This emphasizes the need for detailed examination following initial review using 






















































































































































































Figure 40.  Microarray results for Case 7.  Three 
pathogenic aberrations were detected and were 
determined to overlap pathogenic genes.  a) A 774kbp 
gain was detected on chromosome 1p36.33 which 
overlaps the MDS-related PRDM16 gene.  b) A 249kbp 
gain on chromosome 11p11.2 was observed that 
overlaps the EXT2 gene, known to have tumor 
suppressor roles. c) A 674kbp loss on chromosome 
22q12.1 that overlaps the CHEK2 gene was observed 
and has been shown to play a role in cell proliferation 







Case 9 was a bone marrow aspirate from a 14-year-old male with a normal 
karyotype.  FISH studies were not performed since it was not ordered by the requesting 
physician.  A total of 42 aberrations were detected and classified as benign by microarray 
studies.   
Case 10 
In case 10, we utilized the OncoScan® High-resolution array studies.  It is 
important to note that the ChAS software quality control of the MAPD, a standard deviation 
of the variation of the probe pair ratios, indicated that the quality of these results may have 
been potentially compromised.  The aberrations detected included a 2.5Mbp gain on 
1p36.33 (PRDM16 gene); a 3.7Mbp LOH on 1p34.2 (MPL gene); a 4.0Mbp LOH on 1q25.2 
(ABL2 gene); a 39kbp loss on 2p23.2 (portion of the ALK gene); a 268kbp loss on 6p25.3 
(IRF4 gene); a 417kbp loss on 8p21.2 (CLU gene); a 47kbp loss on 9p21.3 (CDKN2B 
gene); a 6.0Mbp LOH on 9p21.1 (PAX5 gene); a 3.8Mbp gain on 9q34.11 (ADAMTS13 
gene); and a 32.6Mkbp gain on 16p13.3 (ERCC4 and MYH11 gene) (Table VI).  These 
genes have functions ranging from apoptosis, oncogenic potential, and tumor 
suppression.  Other genes detected have known disease associations including AML, 
ALL, TCP, FA, NHL, MDS, and chronic myelogenous leukemia (CML).   
Case 11 
Case 11 was a bone marrow aspirate from a 7-year-old male that presented an 
abnormal cytogenetic karyotype of 45,XY,-7 in seven cells and positive for monosomy 7 
by FISH in 12% of interphase cells (Figure 41).  Due to the low-level mosaicism of this 

































































































































































































































































































































































































































pathogenic aberrations were detected utilizing OncoScan®.  The aberrations detected 
included a 47kbp loss on 9p21.3 (CDKN2B gene); a 4.4Mbp LOH on 9p13.3 (PAX5 gene); 
a 32.6Mbp gain on 16p13.3 (ERCC4 and MYH11 gene); a 1.1Mbp gain on 16q24.3 
(FANCA gene); and a 3.5Mbp gain on 17q12 (RARA gene) (Table VII).  These genes have 
been associated with tumor suppression and also have known disease associations with 
AML, ALL, CML, TCP, and FA.   
Case 12 
Case 12 was a peripheral blood from a 7-month old male with an abnormal 
cytogenetic karyotype of 45,XY,-7 in four cells and positive for monosomy 7 by FISH in 
23% of interphase cells.  The remaining probes in MDS FISH studies were not requested 
(Figure 42).   Two aberrations were determined to overlap with pathogenic genes using 
OMIM and NCBI.  A 197kbp gain was observed on chromosome 6p25.3 located at chr6: 
241,540 - 439,182 which overlaps with the IRF4 gene (6: 391,738 - 411,442), a known 
oncogene.  A 298kbp loss on chromosome 7p12.2 located at chr7: 50,173,182 - 
50,471,578 was also observed that overlaps with the ALL-related IKZF1 gene (7: 
50,303,464 - 50,405,100) (Figure 43).  
Case 13 
Case 13 was a bone marrow aspirate from a 15-year-old female presenting an 
abnormal cytogenetic karyotype of 45,XX,-7 in nine cells and positive for monosomy 7 in 
28% of interphase cells by FISH (Figure 44).  A total of 45 benign changes were observed 
by microarray.  The level of mosaicism for this case was slightly above the validated 
detection rate for this assay (20-25%), yet monosomy 7 was not able to be detected by 






























































































































































































































































































































































































































































































































































































































































































Case 14 was a bone marrow aspirate from a 15-year-old female with a normal 
karyotype and FISH studies.  High-resolution array studies depicting only benign 
aberrations was observed.   
Case 15 
In case 15, microarray detected three aberrations that overlapped pathogenic 
genes.  A 179kbp loss was observed on chromosome 6p25.3 located at chr6: 222,619 - 
402,086 which overlaps a portion of the IRF4 gene (6: 391,738 - 411,442), a known 
oncogene.  On chromosome 11q22.1 located at chr11: 101,752,252 - 102,239,809, a 
287kbp loss was observed that overlaps the YAP1 gene (11: 102,110,253 - 102,233,422), 
a gene with apoptotic functions.  A 288kbp partial loss in the PTPN11 gene (12: 
112,418,731 - 112,509,917), known to be associated with MDS, was detected on 
12q24.13 (chr12: 112,744,633 - 112,983,024) (Figure 45a-c).   
Case 16 
Case 16 was a bone marrow aspirate from a 19-year-old female presenting normal 
cytogenetic and FISH analyses and two pathogenic aberrations by microarray.  A 690kbp 
gain overlapping the MDS-related PRDM16 gene (1p36.33) and a 216kbp loss 
overlapping a portion of the IRF4 oncogene (6p25.3) was detected (Figure 46).   
Case 17 
DNA from the excess whole bone marrow for case 17 was extracted, however, due 
to a poor quality of DNA (less than 5µg/mL) it could not be used for microarray studies. 




















              
                    
           
Figure 45.  Microarray results for Case 15.  Three 
aberrations overlapping a) a 179kbp loss on 
chromosome 6p25.3 which overlaps with a portion of 
the IRF4 oncogene;  b) a 287kbp loss on chromosome 
11q22.1 overlapping the YAP1 gene, which is involved 
in apoptotic functions; and c) a 288kbp loss partially 
involving the PTPN11 gene located on chromosome 
12q24.13 and implicated in MDS.   
111 
 



















Figure 46.  Microarray results for Case 16.  Two aberrations were 
detected that overlap with pathogenic genes.  a) A 690kbp gain was 
observed on chromosome 1p36.33 which overlaps the MDS-related 
PRDM16 gene.  b) A 216kbp loss on chromosome 6p25.3 that overlaps 







































































































































Case 18 was a bone marrow aspirate from a 13-year-old male with a normal 
karyotype, FISH, and microarray studies.    
Case 19 
Case 19 was a bone marrow aspirate from a 1-year-old male with a normal 
karyotype and FISH results and one pathogenic aberration by microarray.  A 471kbp loss 
was detected on chromosome 1q32.1 located at chr1: 200,239,873 - 200,711,145 and 
was determined to overlap with KIF4 gene (1: 200,551,496 - 200,620,790), a known 
disruptor of the cell cycle (Figure 48).   
Case 20 
Two aberrations were detected by microarray in case 20 and were determined to 
overlap with pathogenic genes.  A 229kbp likely pathogenic loss was observed on 
chromosome 6p21.2 located at chr6: 45,198,969 - 45,428,856 which included a portion of 
the tumor suppressor RUNX2 gene (6: 45,327,799 - 45,664,031).  A 26kbp gain was 
detected on chromosome 16p13.11 located art ch16: 15,801,192 - 15,827,712 that 
overlaps a portion of the AML-associated MYH11 gene (16: 15,703,134 - 15,857,032) 
(Figure 49a-b). 
Case 21 
In case 21, two aberrations overlapping with pathogenic genes were detected with 
normal karyotype and FISH analyses.  A 4,995kbp mosaic gain on chromosome 1p36.33 
including the PRDM16 gene and a 50kbp gain on chromosome 11p11.2 involving the 






































































































































Figure 49.  Microarray results for Case 20.  Two aberrations were detected.  a) 
A 229kbp loss was observed on chromosome 6p21.2 which partially overlaps a 
portion of the tumor suppressor RUNX2 gene.  b) A 26kbp gain was detected on 
chromosome 16p13.11 that overlaps a portion of the MYH11 gene, a gene 










Figure 50.  Microarray results for Case 21.  Image depicts two aberrations that 
overlap with pathogenic genes were detected.  a) A 4,995kbp mosaic gain on 
chromosome 1p36.33 overlapping the MDS-associated PRDM16 gene. b) A 50kbp 
gain on chromosome 11p11.2 was observed that overlaps a portion of the tumor 




Case 22 was a bone marrow aspirate from a 24-year-old female with a normal 
karyotype with suboptimal morphology and was negative for the MDS FISH panel.  Four 
aberrations overlapping pathogenic genes were detected.  A 1.6Mbp gain on chromosome 
1p36.33 overlapping the PRDM16 gene, a known MDS-related gene; a 592kbp loss on 
chromosome 6q25.1 covering LATS1, a large tumor suppressor gene; a 454kbp loss 
involving IDO1 gene with antiproliferative effects; and a large LOH region involving four 
additional genes were detected on chromosome 15.  The genes include: PML (15: 
73,994,672 - 74,047,818), involved in acute promyelocytic leukemia (APL); RPS17 (15: 
82,536,749 - 82,540,543), involved in Diamond-Blackfan anemia; RECQL3 (15: 
90,717,326 - 90,815,461), a known Bloom syndrome gene; and FANCI (15: 89,243,947 - 
89,317,130), known to be involved with Fanconi’s anemia (Figure 51a-d).   
Case 23 
Case 23 was a bone marrow aspirate from a 20-year-old male with a normal 
karyotype, FISH, and microarray results.    
Case 24 
Case 24 was a bone marrow aspirate from a 15-year-old male that presented a 
normal karyotype.  FISH studies using probes for MDS revealed a deletion of 20(q12q13) 
in 8% of interphase cells (Figure 52).  Many benign alterations were noted in microarray 
studies.  The deletion of 20 observed by FISH was not detected by microarray due to low 
























Figure 51a-b.  Microarray results for Case 22. Four aberrations that 
overlap pathogenic genes were detected.  a) A 1613kbp gain was detected 
on chromosome 1p36.33 which overlaps the PRDM16 gene, a known MDS-
related gene.  b) A 592kbp loss was detected on chromosome 6q25.1 which 






















    
Figure 51c-d.  Microarray results for Case 22. c)   A 454kbp loss on 
chromosome 8p11.21 located which overlaps the IDO1 gene, which has 
been shown to have antiproliferative effects on tumor.  d) The image 
illustrates an LOH region on chromosome 15q24.-q26.1 which overlaps four 
genes: PML, involved in acute promyelocytic leukemia; RPS17, involved in 
Diamond-Blackfan anemia; RECQL3, a known Bloom syndrome gene; and 




















Figure 52.  FISH results for Case 24.  The FISH MDS panel detected a 
deletion of 20q12 and 20q13 with normal cytogenetic karyotypes.  This 






Case 25 was a bone marrow aspirate from a 7-year-old female with a normal 
karyotype and negative MDS FISH studies.  A 682kbp pathogenic loss was detected on 
chromosome 7q21.3 located at chr7: 97,143,614 - 97,826,349.  This deletion overlaps the 
TAC1 gene (7: 97,731,958 - 97,740,471), a known regulator of hematopoiesis (Figure 53).    
Case 26 
In case 26, forty-two of the 45 aberrations detected by microarray were classified 
as benign.  Three aberrations were determined to overlap with pathogenic genes.  A 
400kbp loss was detected on chromosome 8p11.21 located at chr8: 41,715,952 - 
42,116,292 which overlaps the KAT6A gene (8: 41,929,478 - 42,051,988), a known AML-
related gene.  A 471kbp loss on chromosome 11q14.2 was detected at location chr11: 
85,499,875 - 85,971,236, overlapping the AML-related gene PICALM (11: 85,957,170 - 
86,069,880).  Additionally, a 396kbp loss on chromosome 11q24.3 was detected at 
location chr11: 128,258,843 - 128,655,819 that overlaps with the AML-related gene ETS1 
(11: 128,458,760 - 128,587,583).  (Figure 54a-c).   
Case 27 
Case 27 was a bone marrow aspirate from a 4-year-old male with a normal 
karyotype and normal FISH results (Figure 55).  DNA from the excess whole bone marrow 
was extracted, however, due to a poor quality of DNA (less than 5µg/mL) it could not be 
























































































































































Figure 54.  Microarray results for Case 26.  Three 
aberrations detected were determined to involve AML-
associated genes.  These include a) a 400kbp loss 
was detected on chromosome 8p11.21 which overlaps 
the KAT6A gene; b) a 471kbp loss on chromosome 
11q14.2 was detected which overlaps the PICALM 
gene; and c) a 396kbp loss on chromosome 11q24.3 
was detected which overlaps the ETS1 gene. 
       
 
       
 































































































































Case 28 was a bone marrow aspirate from a 2-year-old male that presented a 
normal karyotype, FISH and microarray results (Figure 56).   
The utilization of high-resolution techniques allowed for the detection of novel 
genetic changes in this rare group of MDS.  The 33 genes found to have a genomic 
aberration have a variety of functions not typically reported in pediatric MDS.  Those of 
particular importance include the eight genes observed in multiple cases which may have 
implications in MDS based upon the findings of this study.  The gain of the entire MDS-
related PRDM16 gene was detected in six cases along with a variety of other genomic 
aberrations equally of interest due to the novelty of these findings in the pediatric MDS 
population (Table VIII).  The results from this study provides information useful in the 


























































































































CASE CYTOGENETIC AND 
FISH RESULTS 
ADDITIONAL GENETIC 
ALTERATIONS AMONG CASES 
WITH GAIN OF PRDM16 
4 46,XY 
Negative FISH 




Gain of EXT2 (11p11.2) 
Loss of CHEK2 (22q12.1) 
10 46,XY 
Negative FISH 
LOH of MPL (1p34.2) 
LOH of ABL2 (1q25.2) 
Loss of ALK (2p23.3) 
Loss of IRF4 (6p25.3) 
Loss of CLU (8p21.1) 
Loss CDKN2B (9p21.3) 
Loss of FANCG (9p13.3) 
LOH of PAX5 (9p13.2) 
Gain of ADAMTS13 (9q34.2) 
Gain of MYH11 (16p13.11) 
Gain of ERCC4 (16p13.12) 
16 46,XX 
Negative FISH 
Partial Loss of IRF4 (6p25.3) 
21 46,XY 
Negative FISH 
Partial Gain of EXT2 (11p11.2) 
22 46,XX 
Negative FISH 
Loss of LATS1 (6q25.1) 
Loss of IDO1 (8p11.21) 
LOH of PML (15q24.1) 
LOH of RPS17 (15q25.2) 
LOH of RECQL3 (15q26.1) 
LOH of FANCI (15q26.1) 
 
Table VIII.  Characterization of the cases with the PRDM16 gene 
aberration.  This table lists the six cases with the PRDM16 gain and their 
respective cytogenetic and FISH results and additional genetic alterations observed 
by microarray analysis.   
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Comprehensive Testing Results 
From the retrospective study, 10.5% of abnormal samples were detected by FISH 
studies alone while 2.6% of abnormals were detected by cytogenetic karyotyping alone.  
This study presents that a total of 13.1% of abnormal samples were detected because of 
concurrent use of cytogenetics and FISH (Table IX).   
The addition of microarray as an adjunct study improved the abnormality detection 
rate for a number of cases.  Table X depicts comprehensive results after using all three 
techniques.  Eleven cases had normal cytogenetics and FISH while microarray detected 
an abnormality.  Twenty-four cases had all three tests performed, seven of these cases 
were normal (29%; 7 / 24) and 17 cases were abnormal (71%; 17 / 24).  Of these 17 cases, 
there were 11 cases with pathogenic findings by microarray with normal conventional 
cytogenetics and FISH studies.   
It is noteworthy that even though an abnormal finding was detected by microarray, 
in four cases microarray did not identify low level mosaic aberrations as low level 
mosaicism is detected by microarray above 20-25%.  A loss of chromosome 7, deletion of 
20, and also a balanced inversion disrupting the MLL gene had gone undetected by the 
microarray technique (Figures 38, 40, and 43; Table VII) .  From this study, 60.7% (17 / 
















































































































































































Table X.  Characterization of results from comprehensive testing.  
This table describes abnormalities for each of the 28 cases analyzed using 
cytogenetic karyotyping, FISH, and microarray techniques.  From this study, 




























MDS has been attributed to age due to the aging of the hematopoietic system from 
gradual accumulation of endogenous and exogenous carcinogens over a lifetime.  Studies 
have shown changes in the HSC system with over time including a higher frequency of 
stem cells, which are typically predominately quiescent, and a shift from a balanced 
differentiation to a more myeloid lineage than lymphoid.  With age, the hematopoietic 
system has an up-regulation of the cell cycle that produces decreased bone marrow 
cellularity that leads to abnormalities of anemia and MDS or MPD (Pang, Price et al. 2011).   
The occurrence of MDS before the age of 50 is rare; MDS is the most common 
cancer in persons over the age of 70 with incidences as high as 50 adult or elderly patients 
per 100,000 annually (Cui, Bueso-Ramos et al. 2010, Tefferi, Vardiman 2009, Corey, 
Minden et al. 2007).  An overwhelming majority of specimens analyzed in our laboratory 
from January 1, 1990 to December 31, 2015 were from the adult and elderly populations 
at 92.4% (3686 / 3992) as seen in Figure 24.  As depicted in Figure 23, this study supports 
the prevalence of MDS over the age of 70; over 53% of the MDS cases received into our 
laboratory were from individuals 70 years and older (1585 / 2948).  In the adult and elderly 
MDS populations, males are more frequently diagnosed than women (Visconte, Selleri et 
al. 2014).  Our study corroborates with the reported literature with findings of 57% males 
(1571 / 2771) to 43% females (1200 / 2771) from the 2771 total adult cases, age 30 and 
above.   
Myelodysplastic syndromes among the pediatric and young adult population, or 
those between the ages of 0 and 29, is quite rare and represents about 5% of the 
hematopoietic neoplastic disorders or about 1.8 to 4 cases per million per year for this age 
group (Rau, Shreedhara et al. 2012, Silva, Maschietto et al. 2013, Germing, Aul et al. 
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2008, Chatterjee, Choudhry 2013, Mandel, Dror et al. 2002).  In the past 25 years, we 
analyzed 306 pediatric or young adult MDS specimens, constituting 7.6% of the total MDS 
samples (306 / 3992), depicted in Figure 24.  This study is one of the largest cohorts of 
MDS and supports previous documentation that is has a low prevalence in the younger 
population.  The current report on pediatric MDS claim that this disease is seen in males 
and females equally (Niemeyer, Baumann 2008, Hofmann 2015a, Glaubach, Robinson et 
al. 2014).  Our study of 119 pediatric only individuals (0-18 years) does not corroborate 
with these reports as depicted in Figure 25 showing a frequency more comparable to the 
adult populations [65 (55%) males to 54 (45%) females].  The results showed a trend that 
males were more often diagnosed with MDS than females in the pediatric population.  
Current literature notes a median age between 6.8 and 10.7 years for pediatric MDS 
(Hofmann 2015a, Hofmann 2015b, Glaubach, Robinson et al. 2014).  Our study depicted 
a slightly lower median age of 6 years in the pediatric (0-18 years) population.  Our study 
of pediatric MDS cases showed that the majority were very young, in the first three years 
of life.  Thus, besides the ratio of males and females in the pediatric population, our 
present study correlates with previously published data on MDS.   
Cytogenetics and FISH 
Once ineffective hematopoiesis is observed, conventional cytogenetic karyotyping 
and FISH are essential tools in accurate diagnosis and provide important prognostic 
information from certain aberrations.  Nearly 40-50% of adult primary MDS studies contain 
a karyotypic abnormality and about 60-80% of secondary MDS samples contain an 
abnormality, detected by conventional techniques (Tefferi, Vardiman 2009, Haase, 
Germing et al. 2007, Jhanwar 2015, Haase 2008, Visconte, Selleri et al. 2014).  The 
heterogeneic nature of MDS includes the presence of different types of chromosomal 
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aberrations but the most common abnormalities in the adult MDS population include one 
or more of the following hallmark abnormalities of -5/del(5q), -7/del(7q), +8, and del(20q) 
(Jhanwar 2015, Haase, Germing et al. 2007, Haase 2008, Visconte, Selleri et al. 2014).  
In the adult population, these chromosome abnormalities have been well 
characterized; to some extent, prognosis and specific treatments have been determined 
based upon the presence of these anomalies.  The most common MDS-associated 
chromosome abnormality is the loss of chromosome 5 or more frequently a deletion of the 
long arm of chromosome 5, observed in about 30% of the adult MDS population with a 
cytogenetic abnormality (Haase, Germing et al. 2007).  As detailed in Table I, our studies 
support this observation in adult MDS samples.  Nearly 33% (519 / 1563) of the total 
abnormal adult MDS samples analyzed in this laboratory presented -5/del(5q).  Monosomy 
7 or deletion of the long arm of 7 is the next most frequent cytogenetic abnormality 
observed in adult MDS at about 15-25% (Jhanwar 2015, Haase 2008).   Our results 
detected -7/del(7q) at a slightly higher frequency of 27% (423 / 1563) among all abnormal 
adult samples.  Over the given time span, 18% of the abnormal adult MDS specimens 
analyzed in our laboratory contained trisomy 8 (282 / 1563) which also corresponds with 
the current statistics of +8 typically seen in roughly 16% of adult MDS (Haase, Germing et 
al. 2007).  Deleted 20q was observed in 16% (260 / 1563) of our subset of abnormal adult 
MDS samples.  Several studies have reported the deletion of the long arm of chromosome 
20 in 10-20% of cytogenetically abnormal MDS studies (Jhanwar 2015).   
Another cytogenetic abnormality typically observed in MDS patients is the loss of 
the Y chromosome, but this abnormality has been associated with advanced age and not 
necessarily indicative of the syndrome (Vardiman, Thiele et al. 2009, Tefferi, Vardiman 
2009).  In our adult and elderly population of MDS, loss of Y was the most frequent 
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cytogenetic non MDS-related abnormality observed at 12% (190 / 1563).  A variety of 
other abnormalities not related to MDS were observed in the adult population, however, 
all in frequencies less than 2%.   
A limited number of reports are available on the characterization of pediatric and 
young adult MDS but we do know that karyotypic abnormalities are typically observed in 
30 to 50% of the pediatric MDS population (Glaubach, Robinson et al. 2014).  Our study 
showed a slightly lower frequency of cytogenetic aberrations in this young population at 
24.8% (76 / 306).  Of the abnormal specimens, 73.7% (56 / 76) contained one of the four 
hallmark MDS-related abnormalities (Table II).  Current studies have documented the 
presence of these specific anomalies in pediatric MDS but research has shown that these 
entities are observed in different frequencies.  Unlike the adult MDS population, -5/del(5q) 
is rarely observed in pediatric MDS (Hofmann 2015a, Germing, Aul et al. 2008).  Our study 
found -5/del(5q) in 10.5% (8 / 76) of our abnormal pediatric population.  This was our least 
frequent cytogenetic abnormality among the four hallmark aberrations.  The most frequent 
cytogenetic abnormality in our pediatric specimens was -7/del(7q) in 36.8% (28 / 76).  
Current literature also shows that this abnormality is the most prevalent in the pediatric 
population at rates of 30% of abnormal cytogenetic studies and is observed in the adult 
population only 15-25% of the time (Corey, Minden et al. 2007, Glaubach, Robinson et al. 
2014, Niemeyer, Baumann 2011, Hofmann 2015a, Hofmann 2015b).  The next most 
frequent abnormality observed in the pediatric population is documented as trisomy 8, 
between 12-16% and in our study we witnessed +8 in 17.1% (13 / 76) (Glaubach, 
Robinson et al. 2014, Hofmann 2015a).  This intermediate frequency is comparable to that 
observed in the adult population.  Finally, the del(20q) abnormality has an intermediate 
frequency about 10-20% in both the pediatric and adult populations (Hofmann 2015a, 
Glaubach, Robinson et al. 2014).  Our study coincides with this information with the 
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observation of del(20q) in 13.2% (10 / 76) of the abnormal pediatric samples.  The most 
frequent other abnormality detected in the pediatric and young adult population is 
constitutional trisomy 21 in 25% (19 / 76).  Trisomy 21 accounts for 20-25% of pediatric 
MDS and has been characterized as its own entity of ML-DS (Rau, Shreedhara et al. 2012, 
Glaubach, Robinson et al. 2014).  The remaining pediatric and young adult samples with 
cytogenetic abnormalities not typical of MDS were observed in frequencies less than 1%.   
This study is one of the largest retrospective studies of MDS with 3992 total MDS 
specimens studied over the time frame of January 1, 1990 to December 31, 2015.  The 
goal of this study was to provide more evidence of the prevalence in the adult population 
and to confirm just how rare a disease MDS is in the pediatric population.  Our study 
confirms the very infrequent occurrence of MDS in the pediatric and young adult 
population.  This study provides confirmation of published statistics on the demographics 
and cytogenetic frequencies in adult MDS.  This study also provides more evidence 
towards the frequencies of cytogenetic findings in the pediatric and young adult population 
and provides evidence that the most common cytogenetic abnormality of -7/del(7q) is seen 
in a slightly higher frequency than previously published.     
Our study supports concurrent cytogenetic and FISH analyses to efficiently and 
accurately detect prognostically important abnormalities in MDS.  Benefits of concurrent 
cytogenetic and FISH testing aid in the detection of cytogenetic aberrations even when 
mitotic index is low from compromised or limited initial specimen and when poor 
morphology inhibits the ability to observe higher resolution banding (Cin, Aster et al. 2010, 
Rigolin, Bigoni et al. 2001).  Utilizing cytogenetic karyotyping will continue to detect 
abnormalities in very low frequencies that may be out of the abnormal range established 
for each FISH probe as determined during probe validation.  Furthermore, this study 
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observed 10.5% (8 / 76) of the total abnormal pediatric/young adult samples containing 
one of the hallmark MDS abnormalities only detectable by FISH studies (Table IX).  An 
accurate determination of all genetic aberrations is of the utmost importance for this rare 
group of MDS and is achieved with concurrent testing.       
Prognostic Implications in MDS 
For MDS studies, the use of cytogenetic studies is of utmost importance in 
prognostic implications based upon the presence of the hallmark aberrations of -5/del(5q), 
-7/del(7q), +8, and del(20q).  In the adult population, the prognostic scores are determined 
and well characterized based upon the presence of these anomalies.  Limited information 
and studies on the pediatric MDS population has precluded the development of a pediatric 
specific prognostic scoring system, however, continued efforts will contribute to this cause.  
The information available has shown prognostically diverse cytogenetic findings between 
the two age groups.   
The loss of chromosome 5 or deleted 5q is the most prevalent aberration in the 
adult population and is rarely observed in the pediatric population.  Adults with -5/del(5q) 
are considered in the ‘good’ prognostic category with an overall median survival at 54 
months and specific drug therapies have long been established including the use of 
azacitidine for MDS with 5q deletions (Tefferi, Vardiman 2009, Zou, Fink et al. 2007)  This 
abnormality in the pediatric population presents poor overall survival and a higher 
propensity of progression to AML (Haase 2008).  
A more favorable prognosis, median overall survival over 2 years, in the pediatric 
population is given when -7/del(7q) is observed cytogenetically due to being the ideal 
candidate for HSCT.  After treatment, these pediatric patients have an overall good 
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prognosis with a longer-term survival.  In the adult population, the median survival of an 
adult MDS study with this abnormality is less than 2 years (Rau, Shreedhara et al. 2012).  
These adult individuals are typically prone to infections and the -7/del(7q) aberration is 
usually part of a more complex karyotype (Greenberg, Tuechler et al. 2012). 
 Trisomy 8 in the pediatric population presents the most stable prognosis of the 
disease in the younger population while in the adult population; this abnormality correlates 
with an intermediate prognosis of OS at or above 23 months.  In both populations, the 
prognostic impact of del(20q) also has an intermediate OS at or above 23 months 
(Greenberg 2015, Rau, Shreedhara et al. 2012).  The -5/del(5q) and -7/del(7q) prognostic 
differences need to be the basis for the justification of characterizing the younger 
population as its own group.  Discovering any trends in gene involvement of the pediatric 
population and making comparisons with the adult studies will aid in determining key 
differences between pediatric and adult MDS cases at the molecular level.   
Microarray 
The use of high-resolution techniques including microarray is useful in the 
identification of any additional microdeletions or duplications that are unable to be 
observed by standard cytogenetic assays.  In the adult population, this technique has been 
able to shed light on possible mutations that affect genes that regulate cellular epigenetic 
machinery (Shih, Abdel-Wahab et al. 2012, Bejar 2014).  The specific genes involved in 
pediatric MDS have yet to be fully characterized and this study contributes to the ongoing 
research of this rare population.   
Our study shows the importance of comprehensive analyses for MDS.  Roughly 
45% of MDS studies will present normal cytogenetic karyotypes yet a genetic imbalance 
cannot be ruled out (Cherian, Bagg 2006, Haase, Germing et al. 2007).  The purpose of 
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this study was to determine genetic anomalies in the rare pediatric MDS population with 
a comprehensive study that included cytogenetics, FISH, and high-resolution array 
technologies.  As described in Table XI, our findings characterized genetic aberrations in 
33 genes from over 58% (15 / 26 cases) of the pediatric and young adult samples tested.  
The majority of these cases (11 cases) presented normal cytogenetic and FISH results at 
73% as depicted in Figure 57.  The ability to detect genomic loss or gain in prognostically 
relevant genes in pediatric MDS cases has clinical implications for the patient and higher 
resolution testing like microarray can achieve this detection.   
This study also shows the need to continue conventional techniques of 
cytogenetics and FISH.    Microarray analysis is typically able to detect copy number 
changes when present in as few as 20-25% of cells.  Unfortunately, due to the mosaic 
nature of cancer genomes, aberrations can occur in low numbers that are not able to be 
detected by these higher resolution tests due to the algorithm nature of the analysis.  The 
need for comprehensive testing is necessary in order to determine all possible genomic 
aberrations for the benefit of a more thorough analysis of each case. 
Current Trends in Adult MDS Array Analysis 
The heterogeneous nature of MDS is seen at the genetic level in a broad spectrum 
of somatic or acquired gene alterations.  Genetic imbalances are detected using high-
resolution techniques that are increasingly becoming recognized as important diagnostic 
and prognostic markers that not only have clinical significance in relation to risk 
stratification and potential therapies but have primarily been studied and implicated in the 
adult population (Vardiman, Thiele et al. 2009, Kulasekararaj, Mohamedali et al. 2013, 








FISH Results Microarray Results Reference 
1 46,XX Negative Loss of CBFA2T3 Fig. 34 
4 46,XY Negative Gain of PRDM16 
Loss of PIM1 
Fig. 35 
5 46,XY del(20)(q12q13) 
[13%] 
Loss of ALK Figs. 37-38 
7 46,XX,inv(11) 
(q13q23) 
MLL (11q23)  
Breakapart [67%] 
Gain of PRDM16 
Gain of EXT2 
Loss of CHEK2 
Figs. 39-40 
10 46,XY Negative Gain of PRDM16 
LOH of MPL  
LOH of ABL2  
Loss of ALK  
Loss of IRF4  
Loss of CLU  
Loss CDKN2B  
Loss of FANCG  
LOH of PAX5  
Gain of ADAMTS13  
Gain of MYH11  
Gain of ERCC4  
Table VI 
11 45,XY,-7 Monosomy 7 
[12%] 
Loss of CDKN2B 
LOH PAX5 
Gain of ADAMTS13 
Gain of ERCC4 
Gain of MYH11 
Gain of FANCA 
Gain of RARA 
Fig. 41 
Table VII 
12 45,XY,-7 Monosomy 7 
[23%] 
Gain of IRF4 
Loss of IKZF1 
Figs. 42-43 
15 46,XY Negative Loss of IRF4 
Loss of YAP1 
Loss of PTPN11 
Fig. 45 
16 46,XX Negative Gain of PRDM16 
Loss of IRF4 
Fig. 46 
19 46,XY Negative Loss of KIF4 Fig. 48 
20 46,XX Negative Loss of RUNX2 
Gain of MYH11  
Fig. 49 
21 46,XY Negative Gain of PRDM16 
Gain of EXT2 
Fig. 50 
22 46,XX Negative Gain of PRDM16 
Loss of LATS1  
Loss of IDO1 
LOH of PML  
LOH of RPS17  
LOH of RECQL3  
LOH of FANCI  
Fig. 51 
25 46,XX Negative Loss of TAC1 Fig. 53 
26 46,XY Negative Loss of KAT6A 
Loss of PICALM 
Loss of ETS1 
Fig. 54 
 
Table XI.  Details of abnormalities observed in pediatric MDS cases by 
microarray.  This table describes the cytogenetic and FISH findings and the specific 
aberrations detected by microarray fort he 26 cases that microarray was performed on.  















Figure 57.  Cytogenetic or FISH results in cases with abnormal microarray 
analyses.  From the 15 total abnormal microarray cases, 73% presented normal 
cytogenetic and FISH results while only 27% had an abnormal cytogenetic or FISH 
analysis.   
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Current contributions of microarray have identified over 40 key MDS-related 
mutations.  The most frequent mutations occur in genes responsible for DNA methylation, 
histone modifications, transcription regulation, tumor suppression, and signal transduction 
in the form of gains or losses (Table XII) (Kulasekararaj, Mohamedali et al. 2013, 
Glaubach, Robinson et al. 2014, Bejar 2014, Shih, Abdel-Wahab et al. 2012, 
Papaemmanuil, Gerstung et al. 2013).    
One possible mechanism for the development of MDS and other hematopoietic 
malignancies later in life includes the dysregulation of epigenetic genes specifically those 
involved in DNA methylation, which concurrently occurs more frequently as a person ages 
(Jhanwar 2015, Zhang, Padron et al. 2015).  The most frequent mutated genes 
responsible for DNA methylation include TET2 and DNMT3A in the adult MDS population 
(Santini, Melnick et al. 2013, Zhang, Padron et al. 2015, Greenberg 2015, Kulasekararaj, 
Mohamedali et al. 2013, Glaubach, Robinson et al. 2014).  Current literature suggests that 
mutations in the form of copy number loss of the TET2 gene are the most frequent 
aberration detected in MDS samples (Santini, Melnick et al. 2013, Zhang, Padron et al. 
2015).  Furthermore, MDS patients with TET2 and loss of DNMT3A genetic abnormalities 
have been shown to respond positively to hypomethylating agents including azacitidine 
for treatment due to their correcting effects on epigenetic abnormalities (Hofmann 2015a, 
Glaubach, Robinson et al. 2014, Kulasekararaj, Mohamedali et al. 2013, Visconte, Selleri 
et al. 2014).  According to current literature, administering these specific treatments to the 
pediatric population is not the ideal therapy as these mutations are rare in children and 
young adults.     
Epigenetic histone and chromatin modifications including methylation is essential 





















Table XII.  List of the most frequent gene alterations in adult MDS.  
According to current literature these genes are responsible for DNA methylation, 
histone modifications, transcription regulation, tumor suppression, and signal 




stem cell population.  In the adult population, certain MDS-related chromosomal 
abnormalities have been linked to specific methylating activities of the EZH2 gene 
including deleted 7q, a frequent cytogenetic aberration in adult MDS.  The loss of this gene 
has been shown to increase myeloid progenitor formation during hematopoiesis (Padron 
et al. 2015, Kulasekararaj, Mohamedali et al. 2013).  Frequent mutations of ASXL1, a 
regulator of histone function, are observed in the adult MDS population in high frequency 
as a copy number loss and has been shown to result in excess blasts and independently 
results in a poor prognosis for those adults with the mutation (Visconte, Selleri et al. 2014, 
Greenberg 2015).  
The most common genetic alterations affecting transcription regulation in the older 
MDS population include RUNX1, GATA2, and ETV6.  Point mutations in RUNX1, also 
known as AML1, are typically associated with a high-risk MDS with a higher propensity of 
AML evolution (Santini, Melnick et al. 2013, Visconte, Selleri et al. 2014).  The AML1 gene 
acts as a regulator of myeloid differentiation and leads to a poor prognosis when mutated.  
Even though, loss of the GATA2 gene has been suggested to be an early indicator of MDS 
initiation; it has rarely been observed in younger MDS cases (Glaubach, Robinson et al. 
2014).  This gene is responsible for hematopoietic cell proliferation and survival (Zhang, 
Padron et al. 2015).  Gene aberrations of ETV6 have adverse prognostic implications in 
MDS as this gene is frequently rearranged with a variety of other genes in a range of 
human cancers including MDS (Bejar 2014, Bejar, Stevenson et al. 2011).   
Genetic alterations of TP53 is commonly observed with complex karyotypes in the 
form of deletions or loss of the gene.  In the adult population, loss of TP53, a critical tumor 
suppressor gene on chromosome 17p13, is associated with the isolated deleted 5q 
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syndrome (Greenberg 2015); this aberration is rarely observed in young populations.  
Mutations of this gene results in malfunctions of cell cycle regulation and DNA repair and 
has been observed in numerous human cancers (Zhang, Padron et al. 2015, Bejar 2014).  
A poor prognosis and a possible resistance to specific treatments and relapse has been 
observed in adult MDS cases with disruption of the TP53 gene (Greenberg 2015).   
A common gain that affects signal transduction in adult MDS cases has been 
documented within chromosome 9p24 resulting in a copy number gain of the JAK2 gene 
and results in a better OS and lowered progression to AML (Zhang, Padron et al. 2015, 
Vardiman, Thiele et al. 2009).  Even though rare in the pediatric population, this alteration 
is one of the most recognized in myeloproliferative neoplasms (MPN) including 
polycythemia vera (PV) and primary myelofibrosis (PMF) and has typically been observed 
in conjunction with trisomy 8 from karyotyping and FISH analyses (Liu, Ying et al. 2012, 
Kulasekararaj, Mohamedali et al. 2013).  Since trisomy 8 is less frequently observed in 
the pediatric population, the presence of concurrent gain within 9p24 is assumed to rarely 
occur.  A FISH probe is not included in our panel and we did not observe the gain of this 
region in our microarray analysis of pediatric MDS cases.        
Current Trends in Pediatric MDS Array Analysis 
To date, over 40 genes have been described in the adult population and alterations 
of TET2, DNMT3A, IDH1/2, EZH2, ASXL1, RUNX1, GATA2, ETV6, TP53, and JAK2 are 
some of the most frequent aberrations; however, these are rare or even non-existent in 
current pediatric data.  Alterations in genes with DNA methylation and histone/chromatin 
functions have yet to be determined in the pediatric and young adult MDS population   
(Glaubach, Robinson et al. 2014).    Limited use of array on the rare population of pediatric 
MDS has presented very few overlapping adult and pediatric gene involvements but 
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mutations of JAK2, GATA2 and RUNX1 have been seen in very low frequencies (Hofmann 
2015b, Hofmann 2015a, Ismael, Shimada et al. 2012).  In about 7% of primary childhood 
MDS, mutations of the GATA2 gene have been observed leading to the assumption that 
this gene is a first hit in pediatric MDS (Kozyra, Hirabayashi et al. 2015).  Currently, an 
increasing number of studies have been conducted on the mutations associated with 
juvenile myelomonocytic leukemia (JMML) and not pediatric MDS as a whole.  The gene 
associations most frequently observed include those involved in RAS/MAPK signaling, 
which controls cell proliferation and apoptosis, including NF1, PTPN11, CBL, NRAS, 
JAK2, and KRAS (Ganapathi, Schafernak et al. 2015, Silva, Maschietto et al. 2013, 
Glaubach, Robinson et al. 2014, Ismael, Shimada et al. 2012).  The use of high-resolution 
microarray is suggested to play an integral part in accurately detecting genomic alterations 
in JMML and delivering a more accurate diagnosis and prognosis for these young patients.  
More information and insight into the molecular basis of pediatric MDS is needed.  Using 
larger pediatric and young adult MDS cohorts will aid in distinguishing novel genomic 
aberrations useful for a better understanding of MDS in this rare group.   
Limitations of this Study 
Pediatric MDS is rare and the number of cases received in a single laboratory are 
scarce.   To add to this, usually a small amount of whole bone marrow or cancer blood 
specimen is obtained from pediatric samples.  Due to the nature of the disease in these 
young patients, the original specimen sent for cytogenetic and FISH analyses was typically 
at or below the recommended amount.  Excess specimen for these patients is most often 
very limited and the elimination of a test or culture for the use of research is unethical.  In 
our laboratory, clinical information on the patients may be limited to demographic 
information with limited follow up information available.   The majority of pediatric MDS 
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specimens had limited to no follow up studies and further clinical information was 
unavailable.   
Gene Involvement in Pediatric MDS 
In the current study, 33 genes that had a gain/loss/LOH in known pathogenic 
genes was observed (Table V).  These genes have not been previously documented in 
pediatric-specific MDS cases.  Disease specific genes, tumor suppressors, oncogenes 
and cell cycle regulators were observed and were typically aberrant in only one case with 
the exception of eight genes.  The genes that were detected to have a copy number 
change in more than one case included: PRDM16, IRF4, MYH11, ALK, CDKN2B, PAX5, 
EXT2, and ERCC4 (Table XIII).     The most notable finding from this study is a copy 
number gain encompassing the entire PRDM16 gene in six cases (21.4%; 6  /  28 cases).  
The genomic studies on pediatric MDS are very rare and there is a dearth of available 
data; therefore, the resulting effect of these genetic alterations is based upon known 
functions of these genes.      
PRDM16 Gene   
The PRDM16 gene, located on chromosome 1p36.33, belongs to the PRDM family 
that is involved in a wide range of biological processes including adipose development, 
cell fate determination, and specific diseases including cardiomyopathy, AML and more 
importantly MDS (Masetti, Togni et al. 2014, Duhoux, Ameye et al. 2012, Shiba, Yoshida 
et al. 2015, Chi, Cohen 2016, Warner, Greene et al. 2014).  Leukemogenesis in humans 
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from disrupted PRDM16.  Research has shown the involvement of PRDM16 in AML and 
MDS with the t(1;3)(p36;q21) rearrangement (MECOM) among older patients and those 
presenting an overexpression of MECOM had a poor prognosis and less success to 
current therapies (Duhoux, Ameye et al. 2012).  This suggests that the promotor region of 
PRMD16 is important in functionality of the gene.  Further studies revealed that 
rearrangements were not limited to MECOM and novel translocation partners including 
ETV6 and IKZF1 were described (Chi, Cohen 2016).  These studies have led to the 
assumption that a differential expression of this gene is involved during dysregulation of 
hematopoiesis (Duhoux, Ameye et al. 2012).  Functional studies for the PRDM16 gene 
have been challenging due to the fact that multiple isoforms exist that have been 
characterized as both an oncogene (PR-lacking domain) and a tumor suppressor (PR-
containing domain) (Chi, Cohen 2016, Warner, Greene et al. 2014).   
The current data on PRDM16 and MDS is not exclusive to the pediatric population 
and has typically been studied using the adult population.  In one pediatric AML study, a 
novel PRDM16 fusion transcript was detected using sequencing techniques and the 
investigators were able to determine that this occurrence was not only a rare finding but 
was observed as an overexpression of the gene (Masetti, Togni et al. 2014).  Our findings 
in this pediatric and young adult cohort indicated a gain of the entire gene in six cases, 
which is assumed to lead to the overexpression of the PR-lacking domain and therefore 
having an oncogenic effect.  In all cases with PRDM16 alterations, conventional 
cytogenetics was normal.  Each case presented aberrations exclusive to the case 
including gains, losses, and/or LOH in PIM1, EXT2, CHEK2, MPL, ABL2, ALK, IRF4, CLU, 
CDKN2B, FANCG, PAX5, ADAMTS13, ERCC4, MYH11, LATS1, IDO1, FANCI, PML, 
RPS17, and RECQL3 (Table VIII).  Two cases had a common loss of the IRF4 (6p25.3) 
gene with gain of PRDM16 and both cases presented normal cytogenetic karyotypes and 
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FISH findings (Table VI and 46).  A different set of cases had a common gain of EXT2 
(11p11.2) with gain of PRDM16 and only one of the cases presented normal conventional 
cytogenetic findings (Figures 40 and 50); the other case contained an abnormal 
inv(11)(q13q23) by cytogenetics and FISH (Figure 39).  One case with the PRDM16 gain 
also contained a loss of the PIM1 gene on 6p21.2 and presented normal cytogenetic and 
FISH results (Figure 35).  Finally, one case contained PRDM16 aberration with multiple 
other aberrations within 6q, 8p, and 15q by microarray with normal cytogenetic and FISH 
results (Figure 51).  The individual and combined roles of these various genes in cases 
with PRDM16 is yet to be determined.  Also, the determination of whether or not these 
genes are novel translocation partners within the pediatric MDS population needs to be 
established and can be accomplished with continued microarray analysis with a larger 
sample size of young MDS patients.  The overall number of pediatric MDS cases is 
typically low and when cases are received, adequate amount of leftover specimen must 
be made available for DNA extraction to use in higher resolution testing.  The novel 
findings in the PRDM16 gene from this study has potential for being deemed a key player 
in the genetic landscape of the pediatric and young adult MDS population.   
IRF4 Gene   
In four cases, an aberration of the IRF4 gene on 6p25.3 was detected ranging from 
179kbp to 268kbp gain.  One case contained numerous additional copy number changes 
with normal cytogenetic and FISH results.  One of the four cases contained a 197kbp gain 
of the gene along with the loss of the IKZF1 gene.  This case also presented abnormal 
cytogenetic and FISH results of monosomy 7 (Figures 42-43).   The other two cases had 
a partial loss of the gene and both presented normal cytogenetic and FISH results.  In 
addition to the IRF4 gene, one case detected the loss of the YAP1 and PTPN11 genes 
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(Figure 45) and the other case detected gain of PRDM16 (Figure 46).   The IRF4 gene is 
a known oncogene involved in T-cell lymphoma and multiple myeloma primarily and less 
often associated with MDS (Lohr, Stojanov et al. 2014, Kalb, Feldman 2015).  The IRF4 
gene has been shown to function as a transcription factor involved in normal blood 
development, which is needed for key developmental stages of hematopoiesis (Adamaki, 
Lambrou et al. 2013).  One study presented that the amount of IRF4 gene expression in 
pediatric acute leukemia was twice the amount in comparison to healthy children 
(Adamaki, Lambrou et al. 2013).  While another study determined that IRF4 aberrations 
were more commonly observed in a subtype of B-cell lymphoma in the pediatric population 
and less commonly seen in adults (Salaverria, Philipp et al. 2011).  From our study, the 
genomic aberration detected in this gene among the four cases is typical of current 
research observing gains.  Even though studies have not been conducted in the MDS 
populations, our findings are significant for the ongoing research in determining the 
genomic landscape of this cohort.   
MYH11 Gene   
A protein-coding gene associated with AML was detected and was of particular 
interest to this study.  A gain of the MYH11 gene on 16p13.11 was detected in three 
pediatric MDS cases by microarray analysis.  Two of these cases had the exact same gain 
size and numerous additional aberrations were detected by microarray (Tables VI and 
VII).  These two particular cases were either cytogenetically normal or presented 
monosomy 7 (Figure 41).  One case with normal cytogenetic and FISH findings also 
detected a loss of the RUNX2 gene by microarray analysis (Figure 49).  MYH11 is typically 
observed in AML and presents abnormal bone marrow eosinophils and is part of one of 
the most frequent AML-related alterations with the CBFB inversion of chromosome 16 
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usually following drug therapy (Akiyama, Yamamoto et al. 2015, Haferlach 2015).  The 
MYH11 inversion is frequently observed by cytogenetic and FISH analyses in acute 
myelomonoblastic leukemia, but a few studies have documented the presence of cryptic 
aberrations of MYH11 that are only seen with higher resolution testing usually in RT-PCR 
(Douet‐Guilbert, Chauveau et al. 2015).  The evolvement of MDS to AML cannot be ruled 
out without further clinical data for these cases.  Although microarray has not been 
implicated in specific studies to detect MYH11 involvement, the higher resolution 
technique may have uncovered this aberration without CBFB in this cohort of patients for 
the first time.   
ALK Gene   
In two cases analyzed, a partial loss of the ALK gene was detected on 
chromosome 2p23.  ALK has predominately been characterized as a gene involved in a 
variety of tumors including anaplastic large cell lymphomas, follicular lymphoma, non-
small cell lung cancer, and neuroblastoma (Tanaka, Ohwada et al. 2012, Dai, Kelly et al. 
2012).  Currently, there are no studies indicating an ALK involvement in MDS and the 
information available typically presents a variety of ALK-negative lymphomas with MDS 
(Tanaka, Ohwada et al. 2012).  In the two cases this aberration was detected, a partial 
deletion was observed in each of the cases with losses of 39kbp and 98kbp.  The 98kbp 
partial loss case presented normal cytogenetic and FISH findings.  We detected numerous 
additional gains, losses, and regions of LOH.  The other case contained a 39kbp partial 
loss of ALK as the sole aberration from microarray studies.  This case presented normal 
cytogenetic results and abnormal FISH findings (deleted 20q in 13% of interphase cells) 
(Figures 37-38).  ALK-positive gene rearrangements are in fact present in pediatric 
diseases but primarily in neuroblastomas (Jongmans, Loeffen et al. 2016).  In 2010, one 
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study presented a very small population of pediatric MPD patients (6 patients) with ALK 
abnormalities only seen by cytogenetics in the form of inv(2), translocations between 2p 
and 2q or 4q, or a deletion of 2p. Three of these previously published case studies also 
contained the common monosomy 7 aberration (Röttgers, Gombert et al. 2010).  In our 
present study, the cytogenetic findings were normal.  The expression of ALK activates a 
variety of signaling pathways including hematopoietic cell proliferation and transformation 
(Röttgers, Gombert et al. 2010).   With the limited studies available on ALK aberrations 
and MDS, we speculate that the activity of ALK has a variety of activities not limited to 
lymphomas including roles in hematopoietic cell proliferation and transformation.   
CDKN2B, PAX5, and ERCC4 Gene 
In two cases, the same 47kbp loss on 9p21.3 and 32635kbp gain on 16p13.13 was 
observed.  The loss of CDKN2B and gain of the region overlapping the ERCC4 gene 
locations were the exact same in both of these cases.  Both cases contained other 
additional aberrations.  One case presented monosomy 7 by cytogenetics and FISH while 
normal findings were observed in the other case.  These aberrations encompassed the 
CDKN2B and ERCC4 genes, respectively.  Mutations of the CDKN2B gene, a tumor 
suppressor, has been linked to a variety of cancers including melanoma, renal cell 
carcinoma and breast cancer but have not typically been linked to MDS (McNeal, Liu et 
al. 2015, Jafri, Wake et al. 2015).  In a 2012 study, characterization of the methylation 
changes were characterized in chromosome 9p21, which includes the CDKN2B gene, and 
their alterations were considered to play a role in MDS and AML in these patients 
(Cechova, Lassuthova et al. 2012).  This study did not define the age groups of its subset 
of MDS and AML patients nor a genomic copy number change.  The loss of this tumor 
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suppressor in two cases from our study should not be disregarded due to the lack of 
published data and is of interest for further studies.    
The ERCC4 gene has been characterized as a key player in DNA damage repair 
and mutations are typically observed in HPV-positive cervical cancer, neurological 
abnormalities, and more note-worthy, in ERCC4-related Fanconi’s anemia (FA)  
(Manandhar, Boulware et al. 2015, Ghafouri-Fard, Fardaei et al. 2016, Dong, Nebert et al. 
2015).  The ERRC4 gene has enzymatic activity that encodes for important DNA repair 
enzymes and has been studied as a potential target for cancer treatments (Manandhar, 
Boulware et al. 2015).  More importantly, this DNA repair gene, when mutated, causes a 
subtype of FA characterized by bone marrow failure and a predisposition to cancer 
(Bogliolo, Schuster et al. 2013).  Whether this patient is in fact diagnosed with FA is not 
known at this time but the occurrence of this aberration can be used as a gene indicator 
for bone marrow disorders due to inherited disorders.   
A 4.0-6.6Mbp region of LOH on chromosome 9p13.2 was detected in two cases 
encompassing the PAX5 gene (Tables VI and VII).  Typically, alterations of the PAX5 have 
been observed in ALL cases (Anderl, König et al. 2015).  A more recent study recognized 
a number of genes that are considered to cause familial MDS and a predisposition to MDS 
and AML in adult populations including the PAX5 gene (Churpek 2014, Horwitz 2013).  
This finding with novel studies on PAX5 playing a role as a hereditary factor in MDS and 
leukemia risk is of importance in characterizing the genetic landscape of this young 
population.   
EXT2 Gene   
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An aberration of the tumor suppressor gene EXT2 was observed in the form of a 
gain on chromosome 11p11.12 in two cases with the same additional aberration of gain 
of PRDM16.  One case presented abnormal cytogenetic and FISH findings with an 
inversion of chromosome 11 and additional aberrations in CHEK2 by microarray analysis 
(Figures 39-40).  A 50kbp partial gain of EXT2 was detected in a case that contained gain 
of PRDM16 and normal cytogenetic and FISH results (Figure 50).  The EXT2 gene causes 
abnormal bone growths or exostoses and has been found to play a role in hereditary bone 
cancers (Wuyts, Van Hul et al. 1998).  This gene has typically been characterized as a 
tumor suppressor primarily involved in osteochondromas with genetic mutations of loss or 
nucleotide substitutions (Stickens, Clines et al. 1996, Xia, Xu et al. 2016).  This aberration 
has not been documented as a gain or with an involvement in MDS but it was detected in 
two cases with the same concurrent gains and should be one to note for future studies.  
Protein Coding Genes of MDS, MPN, and AML:  RUNX2, IKZF1, ETS1, 
PTPN11, PML, and CBFA2T3 Genes 
A 229kbp loss on chromosome 6p21.was detected in one patient that overlaps 
with the protein coding gene RUNX2.  This patient presented normal cytogenetic and FISH 
results and also had a gain of MYH11 observed by microarray analysis (Figure 49).  
RUNX2 is most often associated with bone and cartilage maintenance but in knockout 
studies, defects in this gene have caused disruption in the hematopoietic development 
(Harada, Harada et al. 2004, Blyth, Cameron et al. 2005).  Presently, the majority of 
studies focus on RUNX1 aberrations which are found in about 20% of AML patients (Kuo, 
Zaidi et al. 2009). However, a recent study reported the up-regulation of RUNX2 in AML 
with normal cytogenetics (Schnerch, Lausch et al. 2014).   On the contrary, we observed 
the loss of the RUNX2 gene but with limited information regarding RUNX2 overall, we do 
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not dismiss this finding due to the role the RUNX family transcription factors have been 
shown to play in hematopoiesis.   
A loss was detected within the protein-coding gene of IKZF1 that was 298kbp in 
size in one case that also contained a gain of the IRF4 gene by microarray (Figure 43).  
The IKZF1 gene is located on 7p12.2, has more frequently been associated with ALL, and 
presents a poor outcome in B-ALL in the pediatric population (Kuiper, Waanders et al. 
2010).  In 2010, a study characterized IKZF1 as one of the novel mutations found in MPNs 
in the general population so the occurrence of these mutations specifically in pediatric 
MPNs or even MDS has not been documented (Tefferi 2010).  Defects of this gene have 
been shown to cause a malfunction in normal hematopoiesis and is one of the key players 
in regulating hematopoietic stem cell functioning (Gorzkiewicz, Walczewska 2015).  The 
case with loss of the IKZF1 gene in our study presented monosomy 7 cytogenetically.  The 
defined role this gene plays in pediatric MDS specifically has yet to be established; 
however, the loss of chromosome 7 is more frequently observed in the young population 
and therefore a loss of the IKZF1 gene is a possible important candidate gene of pediatric 
MDS.   
A 396kbp loss on 11q24.3 was detected in the protein-coding gene ETS1 in one 
case with normal cytogenetic and FISH results and additional aberrations in KAT6A and 
PICALM by microarray (Figure 54).  This gene belongs to a family that is involved in stem 
cell development, apoptosis, and tumorigenesis (Dittmer 2003).  More importantly, this 
gene has been linked to apoptosis in low-risk MDS patients as an epigenetic regulator in 
methylation (Del Rey, O'Hagan et al. 2013).  This finding is one of particular interest since 
mutations of epigenetic regulators are typically more common in adult and elderly MDS 
and the case described in the report is from an 11-month old (Aul, Bowen et al. 1998).  
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More interestingly, ETS1 has been implicated in FA in a particular subset of the population; 
the downregulation of this gene was observed in the Indian population presenting FA 
(Shyamsunder, Ganesh et al. 2013).  Fanconi’s anemia is typically characterized by bone 
marrow failure and hematological abnormalities and could play a role in this patient’s 
diagnosis of MDS. 
A 288kbp loss on chromosome 12q24.13 overlapping the PTPN11 gene was 
detected in one case with additional genetic aberrations in IRF4 and YAP1 (Figure 45).  
PTPN11 is associated with JMML, AML, and more noteworthy, pediatric MDS (Kozyra, 
Hirabayashi et al. 2015, Olsson, Zettermark et al. 2016, Sarper, Gelen et al. 2015).  
PTPN11 helps regulate cell growth, differentiation, and transformation (Kozyra, 
Hirabayashi et al. 2015).  This aberration has been described in current literature using 
gene based technologies including next generation sequencing and is frequently observed 
in MDS and when present, has been associated with a poor outcome including a shorter 
overall survival (Alpermann, Haferlach et al. 2015, Bejar 2014).  This finding is significant 
for this study as this particular case presented normal cytogenetic and FISH results; this 
loss was only detected using higher resolution testing like microarray.  The ability to detect 
genomic loss in relevant genes like PTPN11 in pediatric MDS cases has prognostic 
implications for the patient and emphasizes the need for concurrent genetic testing. 
The PML gene is often associated with the cytogenetic acute promyelocytic 
leukemia (APL) translocation t(15;17) with the RARA gene, frequently observed by 
karyotyping and/or FISH analyses (Rose, Haferlach et al. 2015).  This aberration is rare 
in MDS patients and the one case that detected a region of LOH on 15q24.1, 
encompassing the PML gene, was negative for the PML/RARA translocation based upon 
cytogenetic karyotyping.  In fact, cytogenetic and FISH results were normal.  However, 
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numerous additional aberrations were detected in PRDM16, LATS1, IDO1, RPS17, 
RECQL3, and FANCI genes by microarray (Figure 51). The detection of this aberration 
provides important diagnostic and prognostic information for APL and in a few rare cases, 
an aberration has been detected as a cryptic anomaly not observed by conventional 
techniques but rearrangements with RARA is also observed (Gruver, Rogers et al. 2013).  
Genomic imbalances of the RARA gene were not observed in this case by microarray 
analyses.  One study of the PML gene used microarray techniques to characterize loss of 
the gene in a variety of lymphomas and carcinomas yet LOH was not detected (Gurrieri, 
Capodieci et al. 2004).  The LOH of PML in this case cannot be discredited due to the 
multitude of aberrations observed by microarray and should be researched further. 
A 532kbp gain of the CBFA2T3 gene was observed in one patient as the sole 
anomaly detected by microarray analysis (Figure 34).  This gene is located on 16q24.3 
and has typically been observed in young AML patients that present a poorer outcome 
and a higher risk of relapse (Schuback, Alonzo et al. 2014).  According to current literature, 
an inversion of chromosome 16 encodes for a CBFA2T3/GLIS2 (16p13.3) fusion protein 
and has been shown to lead to a more aggressive type of pediatric AML (Gruber, Gedman 
et al. 2012).  This inversion typically is cryptic and presents a normal karyotype and 
cytogenetic results on this particular case did not present aberrations of the 16 
chromosome and were in fact normal (Masetti, Pigazzi et al. 2013, Vogan 2013). These 
findings are of particular interest due to the age of the patient (2 years) with an initial 
clinical diagnosis of MDS.  Given the published reports and facts that alteration of 
CBFA2T3 was observed as a sole abnormality, it would be of interest to determine whether 
this genetic change confers aggressive disease with higher transformation potential from 
MDS to AML.  The potential of AML evolvement from MDS is of concern for this particular 
case due to these findings.     
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Inherited Bone Marrow Failure Disorder Genes: FANCG, RPS17, RECQL3, 
FANCI, and FANCA Genes 
 An 11.7Mbp loss on 9p13.3 was detected in one case that overlaps with the 
FANCG gene.  This case contained numerous additional aberrations by microarray and 
presented normal cytogenetic and FISH results.  The observance of the FANCG gene has 
been attributed to the onset of adult AML and is considered a founder mutation of 
Fanconi’s anemia in different populations (Park, Chung et al. 2013, Wainstein, Kerr et al. 
2013, Duan, Wang et al. 2013).  The presence of bone marrow disorders, including MDS, 
are common from IBMF disorders like FA (Zierhut, Tryon et al. 2014).    
A large region of LOH was observed in one case on chromosome 15q25.2-26.1, 
with numerous additional aberrations by microarray (Figure 51).  This LOH region 
encompassed three genes of particular interest for this study.  The RPS17, RECQL3, and 
FANCI gene were within this region and are especially notable due to their involvement in 
three different kinds of inherited bone marrow failure disorders and their associations with 
MDS evolvement.  RPS17 is a gene associated with Diamond-Blackfan anemia, a form of 
anemia that usually presents itself within the first year of life (Babushok, Bessler 2015).  
Diamond-Blackfan is one of the IBMF disorders that leads to abnormal blood cell formation 
and can lead to blood cancers and disorders, including MDS, later in life (Quarello, Garelli 
et al. 2012).  RECQL3 is a gene responsible for the rare genetic disorder of Bloom 
syndrome; typically presents patchy red skin and short statue; more importantly, patients 
with diagnosed Bloom syndrome have a higher risk of different cancers (Aktas, Koc et al. 
2000).  Bloom syndrome predisposes an individual to AML and MDS and usually presents 
monosomy 7 by karyotyping, a common aberration observed in the pediatric MDS 
population (Poppe, Van Limbergen et al. 2001).  Microarray findings in this case also 
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showed LOH of the FANCI gene, one of the 17 variants that are responsible for FA that 
causes defective DNA repair functions, which leads to an inherited form of bone marrow 
disorders (Chen, Zhang et al. 2014).  The three genes detected in this case are 
responsible for three types of IBMF disorders, which have been documented to cause a 
predisposition to MDS and/or AML in the pediatric population (Babushok, Perdigones et 
al. 2015, Babushok, Bessler 2015).  Cytogenetic and FISH analyses for this case were 
normal.   
Aberrations of the FANCA gene were observed in one of the MDS cases.   An 
1110kbp gain on 16q24.3 encompassing the FANCA gene was detected along with 
numerous additional aberrations and is considered a gene of interest for this cohort (Table 
VII).  FANCA gene variants are one of the numerous genes responsible for the activation 
of FA (Ishiai, Kitao et al. 2008).  Individuals with this genomic imbalance have an increased 
risk for MDS and AML from the malfunctioning repair genes responsible for this IBMF 
disorder (Solomon, Rajendran et al. 2015, Voso, Fabiani et al. 2015).  The occurrence of 
this aberration is a probable cause for MDS in this subset of patients.   
Oncogenes and Tumor Suppressors:  MPL, ABL2, KIF14, PIM1, LATS1, CLU, 
YAP1, and CHEK2 Genes 
A 3760kbp region of LOH on 1p34.2 that encompassed the MPL gene was 
detected utilizing the OncoScan® platform on one case.  This particular case contained 
numerous additional aberrations observed by microarray and presented normal 
cytogenetics and FISH results (Table VI).  MPL, a proto-oncogene, has been associated 
with myelofibrosis and thrombocytopenia and one study has found a mutation of the MPL 
gene in pediatric essential thrombocythemia (ET), a very rare disease among the younger 
population (Ouyang, Qiao et al. 2015).  Essential thrombocythemia, when present in the 
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pediatric population, is seen as a sporadic event or as a familial inheritance and leads to 
a predisposition of MDS (Teofili, Giona et al. 2007).   In this same patient, a 4006kbp LOH 
was also observed at chromosome 1q25.2 which potentially disrupts the ALL-related gene 
ABL2 (Figure 42).  To date, the majority of pediatric data available correlates this gene 
with pediatric ALL and AML (Kuiper, van Reijmersdal et al. 2015, Raca, Gurbuxani et al. 
2015).  
In one case, a 471kbp loss was observed in 1q32.1 as the sole aberration detected 
by microarray with normal cytogenetics and FISH (Figure 48).  This loss overlaps the 
protein-coding gene KIF14, identified as an oncogene in a variety of cancers including 
retinoblastoma, lung, breast, and ovarian cancers (Corson, Huang et al. 2005).  KIF14 
functions as a regulator during the cell cycle and interacts with tumorigenic signaling 
pathways and mutations have been linked to cytokinesis failures when mutated (Thériault, 
Corson 2015).  Typically, the genomic aberration of KIF14 is in the form of gains and an 
association with hematopoietic disorders like MDS have yet to be described.  Our results 
conflict with current data, as seen as a loss, yet are noteworthy for future studies as the 
function of KIF14 in MDS is speculated to be fundamentally different then the previously 
described tissue specific activity KIF14.     
PIM1, a proto-oncogene primarily expressed in B-lymphoid and myeloid cells lines 
has an association in hematopoietic malignancies when overexpression occurs (Ouhtit, 
Muzumdar et al. 2015).  This is of particular interest as one case presented a 247kbp loss 
on 6p21.2, resulting in the loss of the PIM1 gene (Figure 35).  This case presented normal 
cytogenetic and FISH results and was a case that also detected an aberration in the 
PRDM16 gene by microarray.  The PIM1 gene belongs to a family of kinases typically 
overexpressed, not inhibited, in tumor cells and the inhibition of PIM1 is currently being 
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studied as a potential drug therapy for hematological cancers (Garcia, Langowski et al. 
2014, Blanco-Aparicio, Carnero 2013).  The presence of this aberration may have a 
relationship with the gain of PRDM16 gene, the aberration also detected by microarray, 
yet data on this co-occurrence has not been described to date.    
The tumor suppressor, LATS1, located on 6q25.1 was detected in one patient with 
a 592kbp loss along with multiple additional aberrations by microarray with normal 
cytogenetics and FISH (Figure 51).  LATS1 helps regulate the cell cycle and apoptosis 
(Xia, Qi et al. 2002).  Mutations of this gene have mainly been found in non-small cell lung 
cancers and mesothelioma (Wan, Sun et al. 2016, Lee 2015).  An association with LATS1 
and MDS is not clear but the apoptotic behavior of this gene leads to a suspicion of an 
involvement in hematopoietic disorders including MDS.  
In one case, multiple aberrations were detected including a 417kbp loss on 8p21.1 
(CLU gene) (Table VI).  The CLU gene, a tumor suppressor, has been implicated in 
pediatric neuroblastoma and more recently as a risk gene in Alzheimer’s disease (Wang, 
Liu et al. 2012, Yang, Li et al. 2016).  The exact role CLU plays in human cancers is still 
under investigation, but roles in apoptosis, proliferation, transformation, and differentiation 
have been documented and more research is needed to determine its place in the genetic 
landscape of MDS.    
A 287kbp loss was observed in 11q22.1, overlapping the YAP1 gene in one case 
with other genetic aberrations by microarray (Figure 45).  YAP1 plays an oncogenic role, 
activates genes involved in cell proliferation, and suppresses apoptotic genes and is a 
gene of interest for this study as studies have shown its expression in hematopoietic stem 
cells and AML (Safari, Movafagh et al. 2014).  Furthermore, YAP1 has been found in cells 
responsible for tumor-repopulation in medulloblastoma in children (Fernandez-L, 
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Northcott et al. 2009).  A consistent expression of YAP1 contributes to the homeostatic 
balance of proliferation and apoptosis in hematopoiesis (Wang, Du et al. 2014).   
A 674kbp loss was detected on 22q12.1 overlapping the CHEK2 gene, a known 
tumor suppressor, in the case that presented inverted 11 by cytogenetic and FISH.  This 
gene is commonly associated with ovarian, breast, and in rare cases pancreatic cancer 
but not typically implicated in MDS (Lawrenson, Iversen et al. 2015, Scelo, McKay et al. 
2014).  Recently, a study found an association with CHEK2 gene alterations being 
association with the development of MPNs including PV (Janiszewska, Bąk et al. 2015).  
This study presents a new player in the molecular mechanisms behind MPNs as they have 
been shown to evolve into MDS and/or AML and hence our detection is noteworthy for 
future studies (Mascarenhas, Mesa et al. 2014). 
Non-Specific Protein Coding Genes:  TAC1, KAT6A, ADAMTS13, PICALM, 
IDO1, and RARA Genes 
TAC1, a gene located on 7q21.3, has been associated with a variety of diseases 
including heart disease, neurodegenerative disease, and more interestingly, has an 
impact on hematopoiesis (Liu, Castillo et al. 2007).  One patient exhibited a 682kbp loss 
overlapping this gene as the only aberration; the cytogenetic and FISH analyses were 
normal (Figure 53).  To date, cases involving pediatric MDS or hematopoietic diseases 
and aberrations of the TAC1 gene are non-existent but with further testing of this young 
group and larger cohorts, a significant contribution may be implied into the role this gene 
plays in the rare pediatric population. 
The protein-coding gene, KAT6A, is located on 8p21.1 and a 400kbp loss 
encompassing this gene was detected in one case along with aberrations of the PICALM 
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and ETS1 genes by microarray (Figure 54). This gene is typically associated with AML, 
specifically containing the translocation with CREBBP, t(8;16); however, this case 
presented normal cytogenetic and FISH findings  (Panagopoulos, Torkildsen et al. 2014).  
Variant gene partners of the KAT6A gene have been determined, some that may be 
cryptic, but the loss of the gene in MDS or more specifically in pediatric MDS has not been 
documented at this time (Saleem, Mohd. Yusoff 2015).   
In one case, a gain approximately 3863kbp in size on 9q34.2 overlapping the 
ADAMTS13 gene.  This gene is known to be involved in thrombocytopenic purpura and 
was observed in addition to other aberrations (Table VII) (Krabbe, Kemna et al. 2015).  
Thrombocytopenia is commonly observed in MDS patients, pediatric and adult (Li, 
Morrone et al. 2015).  
A 471kbp loss in the PICALM gene, located on 11q14.2 was detected in one case 
with normal cytogenetic and FISH findings and additional aberrations detected by 
microarray (Figure 54).  This protein-coding gene is typically observed in Alzheimer’s 
disease (Xu, Tan et al. 2015).  Recently, studies characterized the PICALM gene as a 
regulator in normal hematopoiesis and these studies have begun using PICALM as a 
possible therapeutic target for hematopoietic disorders including PV (Ishikawa, Maeda et 
al. 2015).  A noted loss of function in the pediatric population has yet to be characterized 
but with further research and larger cohorts a better understood role could be established.  
A 454kbp loss was observed in one case in the protein-coding gene IDO1 located 
on chromosome 8p11.21 along with a variety of other aberrations by microarray analysis 
(Figure 51).  This gene has been implicated in a variety of roles including antimicrobial 
and antitumor defense and more importantly, in inflammation (Yeung, Terentis et al. 
2015).  The role this gene plays in pediatric MDS has not been characterized but the 
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dysregulation of the inflammation signaling pathways have been noted as driving forces 
in the MDS development and should be further studied to help define the pathogenesis of 
MDS.  
In one of the cases, multiple aberrations were detected including a 3542kbp gain 
on 17q21.2 (RARA gene).  The RARA gene is typically observed in patients with APL with 
presentation of the t(15;17) rearrangement (Rose, Haferlach et al. 2015).  This 
rearrangement is readily observed by cytogenetic karyotyping and/or FISH analysis.  At 
the time of specimen intake, the FISH probes specific for RARA were not applied due to 
the initial diagnosis.  Cytogenetic karyotyping did not observe the classical APL 
rearrangements and in fact presented monosomy 7 by karyotype (Table VII).  However, 
current studies have documented the PML/RARA translocation in APL as a cryptic 
anomaly (Gruver, Rogers et al. 2013).   
The use of high-resolution microarray techniques allowed the detection of genetic 
changes in more than half of the cases analyzed that previously were determined normal 
by cytogenetics and FISH.  Multiple genes with known functions are now implicated in 
pediatric MDS based upon this study.  Those of particular importance include the gain of 
the MDS-related PRDM16 gene, and aberrations in IRF4, MYH11, and ALK genes.  The 
lack of genetic characterization is due to the rarity of the disease and this study contributes 
to the limited research available on the genetic landscape of pediatric MDS.   
Comprehensive Testing 
Cytogenetic and FISH testing is considered the gold standard of care for MDS 
patients as it provides accurate diagnostic and prognostic information regarding the 
patient (Haase 2008).  These techniques are essential for determining clonality of the 
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disease and are essential tools in therapeutic stratification (Germing, Aul et al. 2008, 
Costa, Valera et al. 2010).   Since over 50% of MDS cases contain a cytogenetic 
abnormality that is able to be observed by conventional karyotyping or FISH, the continued 
utility of combined testing is necessary (Visconte, Selleri et al. 2014).  The key for 
successful diagnoses and treatment is to determine the entire genetic landscape of MDS.  
The addition of another genetic test that increases the detection of abnormal cases will 
help better define this disease and genetic changes that may have prognostic impact.  
Multiple types of tests are needed in order to effectively observe all potential genomic 
aberrations.  This can be accomplished with combined cytogenetic, FISH, and high-
resolution microarray testing.       
Conventional cytogenetic studies are used as an efficient and rapid test to observe 
hallmark MDS-related abnormalities of -5/del(5q), -7/del(7q), +8, and del(20q).  The 
specificity of FISH probes can result in missed aberrations without concurrent testing of 
the entire genome.  Hence conventional cytogenetics is useful.  The use of FISH will allow 
the detection of aberrations even when mitotic index is low, especially where conventional 
karyotyping will not be effective.  This is most useful when the initial specimen is limited 
or compromised.  Fluorescence in situ hybridization allows for the detection of low 
mosaicism aberrations not observed by karyotype because more number of cells are 
scored.  As observed in two pediatric cases studied (Figures 36 and 52), a deletion of 20q 
was only observed using FISH testing due to being detected in low frequencies of 
interphase cells [8% and 13%].  As depicted in Table IX, out of the 76 abnormal 
pediatric/young adult samples over the given time span, 10.5% (8 / 76) contained one of 
the hallmark MDS abnormalities detected by FISH studies alone.  Cytogenetic karyotyping 
from these cases presented normal findings.  Furthermore, two cases detected trisomy 21 
by cytogenetic karyotyping only with normal FISH results due to the specific nature of the 
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probes utilized in the FISH panel.  The use of concurrent cytogenetic karyotyping and 
FISH testing allowed for the accurate detection of genetic aberrations in 13.1% of the total 
number of abnormal pediatric and young adult samples studied in this laboratory from 
1990 to 2015.    
  This study determined the impact of a more comprehensive analysis by the 
addition of higher-resolution microarray testing on this rare population of MDS.   From the 
28 cases that utilized comprehensive testing, an abnormality was detected in 60.7% (17 / 
28) cases by karyotyping, FISH, and/or microarray analyses (Table X).  The use of 
microarray was able to detect copy number gains, losses, or LOH in 33 pathogenic genes 
in 15 of the 28 cases (33%) (Table V).  A notable finding from this study presented that 
the majority of the abnormal microarray cases presented normal karyotype and FISH 
analyses with 11 cases (73%) (Figure 57).   However, among the 27% (4 cases) with 
abnormal cytogenetic/FISH findings, the aberrations were not detected by microarray.  In 
case 5, the deletion of 20q was only observed in 13% of interphase cells by FISH and was 
below the detection rate of microarray.  In three cases that presented monosomy 7 by 
cytogenetic karyotyping and FISH analyses, the percentage of mosaicism was fewer than 
the detection rate or very close to the validated rate.  These findings emphasize the need 
for continued karyotyping and FISH testing in order to detect low frequency mosaicisms.  
In order to detect all prognostically relevant gene aberrations, a comprehensive study 

























The purpose of this study was to decipher the genetic landscape in the pediatric MDS 
population.   Using the available, yet limited, information regarding this rare group we were 
able to shed light on key differences and similarities between adult and pediatric MDS.   
The results from the present study helps to better understand the specific genetic changes 
among pediatric/young adult MDS cases; clinical correlations may consequently aid in 
development of treatments tailored specifically for this age group of MDS cases.  The 
results of this study included: 
1) A confirmation of the rarity of MDS in the pediatric and young adult populations by 
presentation of a total of 306 pediatric or young adult MDS specimens, constituting 
7.6% of the total MDS samples, received into our laboratory from 1990-2015. 
2) The frequency of pediatric MDS has typically been reported to occur in males and 
females equally, however, this study found a frequency more comparable to the 
adult MDS data showing males have a slightly higher occurrence [65 (55%) males 
to 54 (45%) females].   
3) The median age of pediatric/young adult MDS is 6 years according to this study 
which is slightly lower than the current literature documenting a median age 
between 6.8 and 10.7 years for pediatric MDS.  This study also determined the 
highest occurrence of pediatric MDS during the first year of life. 
4) This study supports the current literature showing the most common MDS-
associated chromosome abnormality is -5/del(5q) in the adult MDS population 
(30%), with our findings at 33% of the cytogenetically abnormal adult MDS 
samples (519 / 1563).   Documented studies have shown -7/del(7q) is the next 
most frequent cytogenetic abnormality (15-25%), followed by +8 (16%), and 
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del(20q) (10-20%).    Our results detected -7/del(7q) at 27% (423 / 1563); +8 in 
18% (282 / 1563); and del(20q) in 16% (260 / 1563) of our subset of abnormal 
adult MDS samples from 1990-2015.   
5) These results provide evidence that the occurrence of cytogenetic aberrations 
observed in the young MDS population is not as high as 30-50% as previously 
documented, as this study found an aberration in 76 of the 306 pediatric or young 
adult samples (24.8%).   
6) The occurrence of hallmark MDS-related abnormalities are observed in different 
frequencies in comparison to the elderly population.  The most frequent 
abnormality in our study was -7/del(7q) in 36.8% of the samples (8 / 76) which is 
higher than the limited published information showing this aberration in 30% of 
pediatric and young adult MDS patients.  The next most frequent abnormality 
observed in this study was +8 in 17.1% (13 / 76) followed by del(20q) in 13.2% (10 
/ 76).  The -5/del(5q), the most common abnormality in the adult population, was 
observed at a frequency of 10.5% (8 / 76) from our cohort of young MDS 
specimens, thus adding and confirming to the very limited genetic information 
available in the young MDS cases.   
7) The results from this study prove that the use of higher-resolution techniques can 
aid in the detection of genetic aberrations among cases with normal conventional 
cytogenetics and FISH analyses.  Genetic aberrations in 33 genes were observed 
in over 58% (15 cases) of the pediatric and young adult samples tested using 
microarray; the majority of these cases (73%; 11 / 15 cases) presented normal 
cytogenetic and FISH results.   
8) The use of microarray detailed 33 genes of potential interest for pediatric and 
young adult MDS patients.  The functions of these genes include tumor 
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suppressors, oncogenes and cell cycle regulators as well as disease specific 
genes including MDS, AML, ALL, NHL, and CML.  The following genes exhibited 
copy number changes in more than one case: PRDM16, IRF4, MYH11, ALK, 
CDKN2B, PAX5, EXT2, and ERCC4.  
9) Most importantly, a copy number gain in the MDS-related PRDM16 gene was 
detected in six cases (6 / 26; 23%) with microarray.  This is a new and important 
finding.  This is a unique and novel finding for the pediatric and young adult MDS 
population.   
10) The results from this study prove the importance of comprehensive testing utilizing 
cytogenetic karyotyping, FISH, and microarray techniques in distinguishing the 
most accurate genetic landscape of pediatric MDS.  Our study helped to detect an 
abnormality in 60.7% (17 / 28) of the cases by combined use of conventional 
cytogenetics, FISH, and/or microarray analyses and each technique proved to be 
beneficial in its own right.   
Future Directions 
Over 50% of MDS cases present with normal karyotypes by conventional 
cytogenetics; mainly because abnormal clones existing in low frequency may go 
undetected by conventional cytogenetic studies.  These cases fall into a ‘Good’ IPSS 
category.  Genomic imbalances may be present, however, these aberrations can only be 
determined with more sensitive studies (Papaemmanuil, Gerstung et al. 2013, Bejar, 
Stevenson et al. 2011, Bejar 2014). Fluorescence in situ hybridization techniques, which 
is more sensitive, determines only those alterations for which the probes are used.  The 
addition of a more sensitive microarray study may facilitate the detection of cryptic 
abnormalities and may be helpful in determining genomic imbalances.  From the 26 cases 
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that were available for microarray analysis, over half contained genomic aberrations not 
observed by cytogenetic karyotyping or FISH.  We observed multiple patterns of genetic 
alterations in this group of patients and in order to determine those that are prognostically 
important, future studies utilizing a larger cohort of pediatric MDS are warranted.  The 
implications of aberrations in PRDM16, IRF4, MYH11, ALK, CDKN2B, PAX5, EXT2, and 
ERCC4, genes of particular interest since these were altered in more than two cases, 
have the potential to disrupt normal hematopoiesis.  Our present study provides insight 
into the limited information available for the pediatric MDS population. 
Currently, the NCCN guidelines provide information on the most up to date 
treatments for practical use including the risk/benefit and financial cost strategies in 
regards to the patient outcome, adverse events, quality of life and financial burdens 
(Greenberg 2015).  In order to determine the entire global mutational landscape of 
pediatric MDS, continued efforts need to be made in determining how best to combine 
clinical and genetic information and apply this information in the clinical practice.  A more 
thorough study including cytogenetic karyotyping in conjunction with FISH paired with 
higher resolution microarray studies could determine the most accurate genetic makeup 
of these patients.  We observed genomic aberrations in more than half of the cases that 
presented normal cytogenetic and FISH findings.  Furthermore, due to the inability to 
detect low mosaicism by microarray, the continued use of cytogenetics and FISH is crucial 
for the most comprehensive study for these patients.  Current studies have begun using 
higher sensitive tests including next generation sequencing to detect mutations within 
select nucleotide sequences.  The future of genetic testing should not be limited to 
conventional techniques.  With more information using combined testing and more 
accurate data better clinical correlations can be performed which in turn will facilitate 
therapeutic stratification tailored for this rare group of MDS.   
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The results from this study will supplement the very limited information available 
for pediatric MDS.  Further microarray testing needs to be performed on a larger subset 
of pediatric MDS specimens to determine the true incidences of the genomic alterations, 
specifically PRDM16.  Future testing using sequencing assays will provide a more 
thorough analysis on the current cases and for future patients.  This research has 
presented novel findings and has better characterized the genetic landscape in pediatric 
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Appendix A.  Reagent names and manufacturers 
 
Reagent Manufacturer 
Chang Medium BMC® Irvine Scientific, Irvine, CA 
Colcemid® Irvine Scientific, Irvine, CA 
1XTrypsin-EDTA Irvine Scientific, Irvine, CA 
Methyl Alcohol Mallinckrodt Pharmaceutical 
Glacial Acetic Acid Mallinckrodt Pharmaceutical 
Hanks Balanced Salt Solution Irvine Scientific, Irvine, CA 
Wright's Stock Solution Sigma-Aldrich, St. Louis, MO 
6.8 Gurr's Buffer BDH Laboratory, Poole, England 
LSI® EGR-1 (5q31) DNA Probe Abbott-Vysis, Abbott Park, IL 
D5S23, D5S721 (5p15.2) DNA Probe Abbott-Vysis, Abbott Park, IL 
D7S486 (7q31) DNA Probe Abbott-Vysis, Abbott Park, IL 
CEP 7(D7Z1) DNA Probe Abbott-Vysis, Abbott Park, IL 
LSI® D20S108 (2oq12) DNA Probe Abbott-Vysis, Abbott Park, IL 
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Cytocell Del(20q) Deletion Probe Cytocell, Cambridge, UK 
CEP 8 (D8Z1) DNA Probe Abbott-Vysis, Abbott Park, IL 
0.4% Sodium Chloride and Sodium 
Citrate (SSC) 
Sigma-Aldrich, St. Louis, MO 
0.3% Nonidet P-40 (NP-40) Abbott-Vysis, Abbott Park, IL 
4,6-diamidino-2-phenylindole (DAPI II) in 
Antifade Solution 
Abbott-Vysis, Abbott Park, IL 
CytoScan® Nuclease-Free Water Affymetrix, Santa Clara, CA 
CytoScan® 10X Nsp I Buffer Affymetrix, Santa Clara, CA 
CytoScan® 100X BSA Affymetrix, Santa Clara, CA 
CytoScan® Nsp I Enzyme Affymetrix, Santa Clara, CA 
CytoScan® 10X T4 DNA Ligase Buffer Affymetrix, Santa Clara, CA 
CytoScan® 50µM Nsp I Adaptor Affymetrix, Santa Clara, CA 
CytoScan® T4 DNA Ligase Affymetrix, Santa Clara, CA 
10X Titanium™ Taq PCR Buffer Clontech Laboratories, Takara Bio 
Company, Mountain View, CA 
GC-Melt Reagent Clontech Laboratories, Takara Bio 
Company, Mountain View, CA 
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dNTP Mixture (2.5mM each) Clontech Laboratories, Takara Bio 
Company, Mountain View, CA 
PCR Primer (002) Clontech Laboratories, Takara Bio 
Company, Mountain View, CA 
50X Titanium™ Taq DNA Polymerase Clontech Laboratories, Takara Bio 
Company, Mountain View, CA 
2% TBE Precast Gel Lonza Group LTD, Switzerland 
1% TBE Precast Gel Lonza Group LTD, Switzerland 
USB PCR Marker 50-2000bp Ladder Affymetrix, Santa Clara, CA 
CytoScan® Purification Beads Affymetrix, Santa Clara, CA 
CytoScan® Purification Wash Buffer Affymetrix, Santa Clara, CA 
CytoScan® Elution Buffer Affymetrix, Santa Clara, CA 
CytoScan® 10X Fragmentation Buffer Affymetrix, Santa Clara, CA 
CytoScan® Fragmentation Reagent Affymetrix, Santa Clara, CA 
TrackIt™ 25bp DNA Ladder Life Technologies, Carlsbad, CA 
CytoScan® 5X TdT Buffer Affymetrix, Santa Clara, CA 
CytoScan® 30mM DNA Labeling 
Reagent 
Affymetrix, Santa Clara, CA 
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CytoScan® TdT Enzyme Affymetrix, Santa Clara, CA 
CytoScan® Hyb Buffer Part 1 Affymetrix, Santa Clara, CA 
CytoScan® Hyb Buffer Part 2 Affymetrix, Santa Clara, CA 
CytoScan® Hyb Buffer Part 3 Affymetrix, Santa Clara, CA 
CytoScan® Hyb Buffer Part 4 Affymetrix, Santa Clara, CA 
CytoScan® Oligo Control Reagent 0100 Affymetrix, Santa Clara, CA 
GeneChip® Wash A Affymetrix, Santa Clara, CA 
GeneChip® Wash B Affymetrix, Santa Clara, CA 
GeneChip® Stain Buffer 1 Affymetrix, Santa Clara, CA 
GeneChip® Stain Buffer 2 Affymetrix, Santa Clara, CA 
GeneChip® Array Holding Buffer Affymetrix, Santa Clara, CA 
OncoScan® Somatic Mutation Probe 
Mix 1.0 
Affymetrix, Santa Clara, CA 
OncoScan® Copy Number Probe Mix 
1.0 
Affymetrix, Santa Clara, CA 
OncoScan® Positive Control Affymetrix, Santa Clara, CA 
OncoScan® Negative Control Affymetrix, Santa Clara, CA 
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OncoScan® Buffer A Affymetrix, Santa Clara, CA 
OncoScan® dNTPs (A/T) Affymetrix, Santa Clara, CA 
OncoScan® dNTPSs (G/C) Affymetrix, Santa Clara, CA 
OncoScan® SAP, Recombinant (1U/uL) Affymetrix, Santa Clara, CA 
OncoScan® Gap Fill Enzyme Mix Affymetrix, Santa Clara, CA 
OncoScan® Cleavage Buffer Affymetrix, Santa Clara, CA 
OncoScan® Cleavage Enzyme Affymetrix, Santa Clara, CA 
OncoScan® PCR Mix Affymetrix, Santa Clara, CA 
OncoScan® Taq Polymerase Affymetrix, Santa Clara, CA 
OncoScan® Buffer B Affymetrix, Santa Clara, CA 
OncoScan® HaeIII Enzyme Affymetrix, Santa Clara, CA 
OncoScan® Exonuclease I Affymetrix, Santa Clara, CA 
3% TBE Precast Gel Lonza Group LTD, Switzerland 
NEB Low Molecular Weight Ladder New England Biolabs, Ipswich, 
Massachusetts 




Appendix B.  Equipment product names and manufacturers 
 
Equipment/Supplies Manufacturer 
Thermatron Drying Chamber CDS-5® Venturedyne, Ltd., Holland, MI 
HYBrite™ Abbott-Vysis, Abbott Park, IL 
ThermoBrite™ Abbott-Vysis, Abbott Park, IL 
QIAcube® Automated Robot Qiagen, Redwood City, CA 
Qubit 3.0™ Fluorometer Instrument ThermoFisher Scientific, Waltham, MA 
GeneChip® Scanner 3000 7G Affymetrix, Santa Clara, CA 
GeneAmp™ PCR System 9700 Applied Biosystems, Waltham, MA 
MagnaRack Magnetic Stand Life Technologies, Carlsbad, CA 
NanoDrop® Spectrophotometer ND-1000 NanoDrop Technologies, Inc, Wilmington, 
DE 
1/2" Microtube Tough-Spots Diversified Biotech, Boston, MA 





Appendix C.  Software product name and manufacturers 
Software Manufacturer 
CytoVision® Image Analysis System Leica Biosystems, Buffalo Grove, 
IL 
Chromosome Analysis Suite (ChAS) Software Affymetrix, Santa Clara, CA 
GeneChip® Command Center® 3.2 Affymetrix, Santa Clara, CA 
 
